



Universiteit
Leiden
The Netherlands

Cancer chess: molecular insights into PARP inhibitor resistance

Barazas, M.

Citation

Barazas, M. (2021, December 14). *Cancer chess: molecular insights into PARP inhibitor resistance*. Retrieved from <https://hdl.handle.net/1887/3247064>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3247064>

Note: To cite this publication please use the final published version (if applicable).

Abstract

53BP1 is a chromatin-binding protein that regulates the repair of DNA double-strand breaks by suppressing the nucleolytic resection of DNA termini. This function of 53BP1 requires interactions with PTIP and RIF1, the latter of which recruits REV7 (also known as MAD2L2) to break sites. How 53BP1-pathway proteins shield DNA ends is currently unknown, but there are two models that provide the best potential explanation of their action. In one model the 53BP1 complex strengthens the nucleosomal barrier to end-resection nucleases, and in the other 53BP1 recruits effector proteins with end-protection activity. Here we identify a 53BP1 effector complex, shieldin, that includes C20orf196 (also known as SHLD1), FAM35A (SHLD2), CTC-534A2.2 (SHLD3) and REV7. Shieldin localizes to double-strand-break sites in a 53BP1- and RIF1-dependent manner, and its SHLD2 subunit binds to single-stranded DNA via OB-fold domains that are analogous to those of RPA1 and POT1. Loss of shieldin impairs non-homologous end-joining, leads to defective immunoglobulin class switching and causes hyper-resection. Mutations in genes that encode shieldin subunits also cause resistance to poly(ADP-ribose) polymerase inhibition in BRCA1-deficient cells and tumours, owing to restoration of homologous recombination. Finally, we show that binding of single-stranded DNA by SHLD2 is critical for shieldin function, consistent with a model in which shieldin protects DNA ends to mediate 53BP1-dependent DNA repair.

Cancer Chess:

The Shieldin Complex Mediates

Molecular Insights

53BP1-Dependent DNA Repair

Into PARPi Resistance

Chapter 5

Adapted from:

Sylvie M Noordermeer*, Salomé Adam*, Dheva Setiaputra*, **Marco Barazas**, Stephen J Pettitt, et al.

*Contributed equally

Nature. 560(7716):117-121 (2018)

Main Text

53BP1 is a chromatin-binding protein that regulates DNA double-strand break (DSB) repair by suppressing the nucleolytic resection of DNA termini [1, 2]. This function of 53BP1 requires interactions with PTIP [3] and RIF1 [4-9], the latter also recruiting REV7/MAD2L2 to break sites [10, 11]. How 53BP1-pathway proteins shield DNA ends is unknown but two models best explain their action: in one model, the 53BP1 complex strengthens the nucleosomal barrier to end-resection nucleases [12, 13], whereas in a second model, 53BP1 recruits effector proteins with end-protection activity. Here we describe the identification of such a 53BP1 effector complex, Shieldin, which includes C20orf196 (SHLD1), FAM35A (SHLD2), CTC-534A2.2 (SHLD3) and REV7. Shieldin localizes to DSB sites in a 53BP1- and RIF1-dependent manner and its SHLD2 subunit binds to ssDNA via OB-fold domains analogous to those of RPA1 and POT1. Loss of Shieldin impairs non-homologous end-joining (NHEJ), leads to defective immunoglobulin class switching and causes hyper-resection. Mutations in Shieldin subunit genes also cause resistance to poly(ADP-ribose) polymerase (PARP) inhibition in BRCA1-deficient cells and tumours due to restoration of homologous recombination (HR). Finally, we show that ssDNA binding by SHLD2 is critical for Shieldin function, consistent with a model where Shieldin protects DNA ends to mediate 53BP1-dependent DNA repair.

To discover proteins acting in the 53BP1 pathway, we searched for genes whose mutation restores HR in BRCA1-deficient cells leading to PARP inhibition resistance, a hallmark of 53BP1 deficiency [14-16]. We undertook three independent CRISPR/Cas9 screens that entailed the transduction of BRCA1-deficient cells with lentiviral libraries of single-guide (sg) RNAs (Supplementary Fig. S1A). The resulting pools of edited cells were exposed to near-lethal doses of two clinically used PARP inhibitors (PARPi), either olaparib or talazoparib [17]. We screened both an engineered human RPE1-hTERT *TP53*^{-/-} *BRCA1*^{-/-} cell line (hereafter referred to as RPE1 *BRCA1*-KO) and SUM149PT cells carrying a hemizygous *BRCA1* frameshift mutation. The gene-based results of the screens are found in Supplementary Table 1.

The genes coding for 53BP1 and for the uncharacterized protein C20orf196 were hits in all three screens (Fig. 1A). We also identified *SCAF1* and *ATMIN*, which encode an SR-family protein and a transcription factor, respectively (Fig. 1A). *PARP1* was a hit in the talazoparib-resistance screen, as expected [18], whereas genes coding for proteins acting upstream (H2AX, MDC1, RNF8 and RNF168) or downstream (RIF1) of 53BP1, were hits in the RPE1 *BRCA1*-KO screen (Supplementary Table 1). The presence of 53BP1 and 53BP1-pathway proteins suggested that these screens could reveal hitherto uncharacterized 53BP1 effectors.

In competitive growth assays (Fig. 1B), sgRNAs targeting 53BP1 led to outgrowth of *BRCA1*-KO cells in the presence of olaparib (Fig. 1C; genotyping information in Supplementary Table 2). Similarly, sgRNAs targeting C20orf196, *ATMIN* and *SCAF1* led




FIGURE 1 | Identification of Shieldin.

(A) Venn diagram of the top 20 hits in each screen. (B) Schematic of the competitive growth assays. (C) Competitive growth assays \pm olaparib (16 nM) in RPE1 BRCA1-KO cells. Data represents mean fraction of GFP positive cells \pm SEM, normalized to day 0 ($n = 3$, independent transductions). (D) PARPi resistance caused by mutation of C20orf196. SUM149PT cells transfected with indicated crRNAs were treated with 50 nM talazoparib for 14 d. Relative growth was normalized to a non-targeting crRNA (CTRL). Bars represent mean \pm SD of multiple crRNAs per gene (shown is a representative plot of 2 biologically independent experiments). (E) Domain architecture of Shieldin subunits. SHLD3 contains a REV7-binding PXXXPP motif [19]. (F) Protein interaction network surrounding REV7, C20orf196, FAM35A and CTC-534A2.2. Solid and dashed arrows represent interactions at an FDR of $\leq 1\%$ and $\leq 5\%$, respectively. (G) Sequential affinity purifications from 293T cell lysates expressing the indicated proteins. Bound proteins were immunoblotted with the indicated antibodies ($n = 2$ independent experiments).

to PARPi resistance (Fig. 1C and Supplementary Fig. S1B). In parallel studies, transfection of tracrRNA and crRNAs targeting *C20orf196*, *53BP1* or *PARP1* caused talazoparib resistance in SUM149PT cells (Fig. 1D and Supplementary Fig. S1C). Since *C20orf196* was identified as a hit in all three screens and validated in independent assays, we sought to determine its role in DNA repair.

C20orf196 is an uncharacterized protein of 205 amino acid residues (Fig. 1E) previously identified as a candidate REV7-interacting protein [20]. We used immunoprecipitation coupled to mass spectrometry (IP-MS) to expand the interaction network surrounding these proteins (Fig. 1F and Supplementary Table 3). One protein, *FAM35A*, was enriched in both *C20orf196* and REV7 IP samples (Fig. 1F). *FAM35A* was striking due to the presence of three predicted OB-fold domains (OBA, OBB and OBC; Fig. 1E), reminiscent of those in the single-stranded (ss) DNA binding proteins RPA1 [21] and POT1 [22]. *FAM35A* IP-MS experiments recovered CTC-534A2.2, also identified in the REV7 IP-MS (Fig. 1F and Supplementary Table 3). CTC-534A2.2 is a protein encoded by an alternative mRNA emanating from the *TRAPPC13* locus (Fig. 1E and Supplementary Fig. S1D). sgRNAs against CTC-534A2.2 were not present in either of our first-generation sgRNA libraries. IP-MS with CTC-534A2.2 recovered *C20orf196*, *FAM35A* and REV7 (Fig. 1F and Supplementary Table 3), suggesting that these proteins form a single protein complex, which was confirmed by sequential affinity purification of epitope-tagged *C20orf196*, CTC-534A2.2, *FAM35A* and REV7 (Fig. 1G).

FAM35A, *C20orf196* and CTC-534A2.2 were identified in a fourth CRISPR/Cas9 screen employing a second-generation sgRNA library, TKOv2. This screen sought to identify genes promoting resistance to ionizing radiation (IR) in RPE1 cells (Supplementary Fig. S1E). 75 genes scored at a false discovery rate (FDR) <1% and this gene set was highly enriched in genes encoding NHEJ factors by gene ontology enrichment ($p = 1.11 \times 10^{-11}$, Fisher's exact test with multiple correction; Fig. 2A and Supplementary Table 4). *RIF1*, *FAM35A*, *C20orf196*, CTC-534A2.2, *53BP1* and REV7 were all hits at FDR <1% (Fig. 2A). These data suggest that the complex formed by *C20orf196*, *FAM35A*, REV7 and CTC-534A2.2 promotes DSB repair by NHEJ. For reasons that will become apparent below, we named this complex Shieldin with *C20orf196*, *FAM35A* and CTC-534A2.2 renamed SHLD1, SHLD2 and SHLD3, respectively.

Independent sgRNAs targeting *SHLD2* or *SHLD3* caused sensitivity to the clastogen etoposide in competitive growth assays (Supplementary Fig. S1F) and caused resistance to olaparib in RPE1 *BRCA1*-KO cells, consistent with SHLD2/3 acting with REV7 and SHLD1 (Fig. 2B and Supplementary Fig. S1G). Clonal knockouts of *SHLD1* or *SHLD2* led to olaparib resistance in *BRCA1*-KO cells, with the *SHLD2*-KO resulting in a phenotype that approached that of *53BP1* loss (Fig. 2C). Similar results were obtained with 11 independent clonal knockouts of *SHLD1* in SUM149PT cells exposed to talazoparib (Supplementary Fig. S1H). Furthermore, expressing GFP-SHLD2 in *BRCA1*-KO *SHLD2*-KO cells restored olaparib sensitivity (Supplementary Fig. S1I). Resistance to PARPi in *BRCA1*-KO cells was likely due to restoration of HR, as measured both by RAD51 IR-induced focus

formation and by a reporter for gene conversion, the traffic light reporter assay [23] (Fig. 2D-E and Supplementary Fig. S2A-D).




FIGURE 2 | Shieldin loss promotes PARPi resistance in cell and tumor models of BRCA1-deficiency. (A) CRISPR dropout screen results in RPE1 WT cells exposed to IR. Shown are gene-level normZ scores < 0. (B) Competitive growth assays using olaparib (16 nM) in RPE1 *BRCA1*-KO cells. Data is presented as mean ± SD, normalized to day 0 (n = 3, independent transductions). (C) Clonogenic survival in response to 16 nM olaparib. Representative images are shown (left) and quantified (right). Bars represent mean ± SD (n=9: RPE1 WT and *BRCA1*-KO *SHLD1*-KO; n=3: *BRCA1*-KO *SHLD2*-KO; n=4: *BRCA1*-KO 53BP1-KO; biologically independent experiments). (D) Quantitation of cells with ≥5 RAD51 foci ± 10 Gy IR (6 h recovery). Biologically independent experiments are shown and the bar represents the mean ± SD. From left to right, the number of replicates was n=3 and n=3 (left panel); n=3, n=4, n=3, n=4, n=3 and n=3 (middle panel); and n=4, n=6, n=6, n=6, n=6, n=6 and n=6 (right panel). (E) Assessment of gene conversion by traffic light reporter assay. Biologically independent experiments are shown and the bar represents the mean ± SD (n=3 for WT and 53BP1-KO; n=4 for *SHLD1*-KO, *SHLD2*-KO, and REV7-KO). (F) Kaplan-Meier curve showing tumor-specific survival of mice transplanted with KB1P4 tumor organoids ± olaparib treatment for 80 d (n = 8 per treatment; editing efficiencies found in Supplementary Table 2). P-values were calculated using a log-rank test (Mantel-Cox).





FIGURE 3 | Shieldin accumulates at DSB sites downstream of 53BP1-RIF1 and promotes class switch recombination. (A-B) Representative micrographs of Shieldin subunit accumulation into IR-induced foci in U2OS cells A or at laser-microirradiation sites in RPE1 cells B ($n=3$ biologically independent experiments). (C) Quantitation of B. Points represent individual experiments counting ≥ 100 cells. Bar represents mean \pm SD. (D) Colocalization of GFP-tagged Shieldin subunits with mCherry foci in U2OS-FokI cells upon mCherry-LacR-FokI expression. (E) Quantitation of GFP-SHLD3 or endogenous REV7 focus intensity. Each point represents a cell. Line represents the mean. Data is the aggregate of two biological replicates with a total of 50 and 120 (GFP-SHLD3 and REV7, respectively), 45 and 122, 48 and 112, 54 and 116, 49 and 111, and 117 cells counted for siCTRL, siRIF1, siREV7, siSHLD1, siSHLD2 and siSHLD3, respectively. (F) mCherry-LacR-FokI colocalization with GFP-SHLD2, SHLD2N, and SHLD2C. Mean normalized focus intensity is shown with a total of 52 (SHLD2 and SHLD2N) or 53 (SHLD2C) cells counted ($n=2$, biologically independent experiments). (G) RIF1 co-immunoprecipitation with V5-SHLD3 (representative of two independent experiments). (H) CSR analysis of CH12F3-2 cells following stimulation. Data is represented as the mean \pm SD ($n=3$ biologically independent replicates). (I) Irradiated (25 Gy) CH12F3-2 clones were immunoblotted for RPA2 phosphorylation (representative of three biological replicates).

Next, we tested whether loss of Shieldin causes PARPi resistance in the KB1P mouse mammary tumor model deficient in *Brca1* and *Trp53* (p53) [24]. sgRNAs targeting *Shld1* and *Shld2* led to PARPi resistance in clonogenic survival assays in KB1P-G3 mammary tumor cells and in *Brca1*^{-/-}; *Trp53*^{-/-} mouse embryonic stem (mES) cells (Supplementary Fig. S3A-C). This resistance was also associated with restoration of HR (Supplementary Fig. S3B). Furthermore, transduction of *Shld1*- and



Shld2-targeting sgRNAs suppressed the cell lethality associated with *Brca1* loss in p53-proficient mES cells (Supplementary Fig. S3D). We transduced the same sgRNAs into KB1P4 mammary tumor organoids (Supplementary Table 2) and implanted them into the fat pads of mice. Olaparib treatment was initiated when tumors reached 50-100 mm³ and was continued for 80 days. While all untreated mice succumbed to excessive tumour burden within 20 days, the control group responded to olaparib for the duration of the treatment (Fig. 2F). However, mice implanted with *Shld1*- and *Shld2*-mutated tumours exhibited a partial response to olaparib, with mice succumbing by day 60 (Fig. 2F). We conclude that Shieldin loss causes PARPi resistance in both human and mouse BRCA1-deficient tumour cells by reactivating HR.

As expected of a complex with a direct role in DSB repair, Shieldin accumulates at DSB sites in a 53BP1/RIF1-dependent manner (Fig. 3A-F and Supplementary Fig. S4A-D). Loss of Shieldin components did not impair formation of 53BP1 or RIF1 IR-induced foci, indicating that Shieldin acts downstream of 53BP1-RIF1 (Supplementary Fig. S4E-F). Consistent with this possibility, we observed genetic epistasis between 53BP1 and the Shieldin genes using the RAD51 focus formation assay in RPE1 BRCA1-KO cells (Supplementary Fig. S5A). We also observed

that *SHLD1* and *53BP1* were epistatic in terms of modulating talazoparib resistance in SUM149PT cells (Supplementary Fig. S5B).

Analyses of the dependencies within the Shieldin complex indicate that SHLD3 is the most apical component followed by REV7, SHLD2, and then SHLD1 (Fig. 3C-E, Supplementary Fig. S4A-D, Supplementary Fig. S6, Supplementary Fig. S7C-E and Supplementary Document 1 for mapping details). Indeed, SHLD3 interacts with RIF1, suggesting that it recruits Shieldin to chromatin-bound 53BP1-RIF1 (Fig. 3G and Supplementary Fig. S7F). Further mapping studies suggest that Shieldin consists of a DSB-recruitment module composed of SHLD3-REV7 that binds to the N-terminus of SHLD2 (residues 1-50; Supplementary Fig. S6, Supplementary Fig. S7A-C), and a presumptive DNA-binding module (SHLD2-SHLD1) featuring the OB-fold domains at the SHLD2 C-terminus (SHLD2C residues 421-904; Supplementary Fig. S7A).

To assess the role of Shieldin in NHEJ, we first analyzed class switch recombination (CSR) in CH12F3-2 cells [25]. Mutation of each of the Shieldin subunits compromised CSR, with *Shld1*-edited cells having a reproducibly milder phenotype (Fig. 3H and Supplementary Fig. S8A-C). *Shld2*-KO was epistatic with both *53bp1*-KO and *Shld1*-KO mutations, consistent with them acting in the same genetic pathway (Supplementary Fig. S8B-C). The expression of AID, which initiates CSR, was not altered in Shieldin mutants, consistent with NHEJ deficiency (Supplementary Fig. S8D). Supporting this possibility, *SHLD1* and *SHLD2* mutations impaired random plasmid integration, which occurs largely through NHEJ [26], to an extent similar to that of 53BP1-deficient cells (Supplementary Fig. S8E-F).

The loss of each Shieldin subunit led to IR-induced RPA2 Ser4/Ser8 phosphorylation, a surrogate marker of end-resection [21], suggesting that Shieldin protects DNA ends (Fig. 3I and Supplementary Fig. S8G). Supporting this hypothesis, restoration of HR in Shieldin-defective KB1P-G3 cells was dependent on ATM activity (Supplementary Fig. S3A-B), which promotes DNA end-resection in the absence of 53BP1 [15] or REV7 [11]. In an accompanying paper, Mirman *et al.* [27] show that *Shld2*-mutated cells have increased end-resection at dysfunctional telomeres. Shieldin therefore antagonizes end-resection.

We surmised that if Shieldin is a downstream effector of 53BP1, artificially targeting Shieldin to DSB sites should rescue phenotypes associated with 53BP1 loss. To do this, we fused SHLD2 to the RNF8 FHA domain, which is recruited to damaged chromatin independently of 53BP1 (Fig. 4A). We found that the FHA-dependent targeting of SHLD2 to DSB sites suppressed RAD51 IR-induced focus formation in *BRCA1*-KO *53BP1*-KO cells (Fig. 4B and Supplementary Fig. S9A). These results suggest that SHLD2 mediates 53BP1-dependent DNA repair.

We observed that the FHA-SHLD2C protein, which contains the OB-fold domains, potently suppressed RAD51 recruitment to DSB sites in *BRCA1*-KO *53BP1*-KO cells (Fig. 4B and Supplementary Fig. S9A). This result suggested that DNA binding might underpin the effector function of the SHLD2 C-terminus. To test for DNA

binding activity, we affinity-purified SHLD2C in the presence or absence of SHLD1 (Supplementary Fig. S9B). We observed SHLD2C binding to a radiolabeled ssDNA probe by electrophoretic mobility shift assays (EMSA), and competition with unlabeled oligonucleotides revealed that SHLD2C preferentially binds to ssDNA over dsDNA (Fig. 4C). While SHLD1 is not essential for SHLD2C DNA-binding, its presence increased the amount of SHLD2C purified, and the retarded complex displayed a difference in mobility consistent with the SHLD2C-SHLD1 complex binding to ssDNA (Fig. 4D, lanes 2 vs 5). We estimate the binding affinity of the SHLD2C-ssDNA interaction to be ~10 nM (Fig. 4E and Supplementary Fig. S9C). We conclude that SHLD2C possesses ssDNA-binding activity.

To explore whether ssDNA-binding is involved in Shieldin function, we generated four mutant versions (m1-m4) of the SHLD2 OB-folds by modeling the SHLD2 C-terminus on an RPA1 structure (PDB 4GNX; Supplementary Fig. S9D) [28]. We also employed a splice variant of SHLD2 that disrupts OBB, which we refer to as SHLD2S. We found that




FIGURE 4 | Shieldin is an effector of 53BP1 by binding ssDNA. (A) Schematic for artificially targeting Shieldin to DSB sites. (B) RAD51 IRIF formation 3 h following 10 Gy irradiation in *BRCA1*-KO *53BP1*-KO cells expressing the indicated fusion proteins. The bar represents the mean \pm SD. From top to bottom the number of biologically independent experiments was n=20, n=22, n=12, n=12, n=16, n=4, n=4, n=4, n=4, n=6, n=6 and n=3. (C) EMSA of the SHLD2C-SHLD1 complex isolated from 293T cells (see Supplementary Fig. S9B) incubated with radiolabeled ssDNA \pm unlabelled oligonucleotides (n=2 independent experiments). EV refers to empty vector. (D) EMSA of SHLD2C WT and variants (n=4 independent experiments). (E) Determination of SHLD2C-SHLD1 ssDNA binding dissociation constant (K_d). Mean values are presented \pm SD (n=3 independent experiments). Representative EMSA shown in Supplementary Fig. S9C. (F) Model of Shieldin function. We speculate that the SHLD2 OB-fold domains bind to ssDNA at DSB sites to suppress resection and favour NHEJ.

the m1 and SHLD2S mutants, either in the context of full-length or SHLD2C proteins, were unable to suppress RAD51 focus formation in *BRCA1-KO 53BP1-KO* cells when fused to the RNF8 FHA domain (Fig. 4B and Supplementary Fig. S9A). Expression of full-length SHLD2-m1 and SHLD2S in *BRCA1-KO SHLD2-KO* cells also failed to suppress RAD51 IR-induced focus formation, unlike wild-type SHLD2 (Supplementary Fig. S10A-B). Importantly, both mutants localized to DSB sites (Supplementary Fig. S10C-D) and interacted with the other members of the Shieldin complex (Supplementary Fig. S10E). Therefore, the SHLD2-m1 and SHLD2S mutants are defective in suppressing HR.

Strikingly, the SHLD2C-m1 mutant was completely defective in ssDNA binding (Fig. 4D, lane 3) whereas the SHLD2C-S mutant displayed reduced and aberrant ssDNA-binding behaviour (Fig. 4D, lane 4). Since the m1 mutation produces a protein defective both in ssDNA-binding and suppression of HR, but which is proficient in both complex assembly and DSB recruitment, we conclude that ssDNA binding by Shieldin is critical for 53BP1-dependent DSB repair.

In conclusion, the identification of Shieldin forces us to re-evaluate how DNA end stability is regulated in vertebrates. Indeed, our results are consistent with a model in which Shieldin is the ultimate mediator of 53BP1-dependent DNA repair by binding ssDNA and occluding access to resection nucleases (Fig. 4F). Our discovery of Shieldin also has implications for the management of *BRCA1*-mutated malignancies, as alterations in Shieldin-coding genes may cause clinical resistance to PARP inhibitors.

Materials and Methods

Plasmids

DNA corresponding to sgRNAs were cloned into pX330 (Addgene: 42230, Cambridge, MA, USA), LentiGuide-Puro (Addgene: 52963), LentiCRISPRv2 (Addgene: 52961), or a modified form in which Cas9 was replaced by NLS-tagged GFP or mCherry using *AgeI* and *BamHI* (designated as LentiGuide-NLS-GFP or -mCherry), as described [19, 29, 30]. Sequences of the sgRNAs used in this study are included in Supplementary Table 5. Coding sequences of C20orf196 and the short isoform of FAM35A were obtained from the ORFeome collection (horfdb.dfci.harvard.edu/), archived in the Lunenfeld-Tanenbaum Research Institute's OpenFreezer [31]. The complete coding sequence of the long isoform of FAM35A was generated by combining a synthesized fragment (GeneArt, Regensburg, Germany) corresponding to the long isoform C-terminus using an internal *KpnI* restriction site. The coding sequence of CTC534A2.2 was generated by gene synthesis (GeneArt). The coding sequences were PCR amplified using *AscI* and *Apal* flanking primers and cloned into pcDNA5-FRT/TO-eGFP and pcDNA5-FRT/TO-Flag to obtain N-terminally tagged FAM35A, C20orf196 and CTC534A2.2. pGLUE-HA-Strep-FAM35A was generated by PCR amplification of the long isoform of FAM35A and cloning into pGLUE (Addgene: 15100) using *AscI* and *NotI*. To generate FAM35A

fragments and mutants, standard protocols for primer-directed mutagenesis or self-ligation of truncated PCR-products were used. To generate pcDNA5-FRT/TO-V5-CTC534A2.2, eGFP was replaced by a V5 tag in the cloning vector pcDNA5-FRT/TO-eGFP using *KpnI* and *Ascl* restriction enzymes after which the coding sequence for CTC534A2.2 was PCR-amplified and inserted into pcDNA5-FRT/TO-V5-MCS using *Ascl* and *XhoI* restriction enzymes.

To generate RNF8-FHA fusions, the N-terminus of RNF8 (aa 1-160) was PCR amplified from pcDNA3-RNF8-FHA(1-160)-RNF168 with flanking *Ascl* sites and inserted into pcDNA5-FRT/TO-eGFP-FAM35A. eGFP-(FHA-) fusions of FAM35A were introduced into pCW57.1 (Addgene: 41393) by Gateway cloning using the pDONR221 donor vector. FAM35A amino acid substitution mutations and deletions were introduced by site directed mutagenesis and deletion PCR, respectively.

The REV7 coding sequence was obtained from the ORFeome collection and was cloned into the pDEST-FRT/TO-eGFP vector using Gateway cloning and into the pcDNA5-FRT/TO-Flag vector by PCR amplification. The N-terminal 967 residues of RIF1 were amplified by PCR and cloned into the pDONR221 vector using Gateway technology. The fragment was then integrated into the pDEST-mCherry-LacR vector by Gateway cloning. Plasmids for the traffic light reporter system were obtained from Addgene (pCVL-TrafficLightReporter-Ef1a-Puro lentivirus: #31482; pCVL-SFFV-d14GFP-Ef1a-HA-NLS-Sce(opt)-T2A-TagBFP: #32627).

Cell lines and gene editing

293T and RPE1 hTERT cell lines were obtained from ATCC (Manassas, VA, USA), 293 Flp-In cells were obtained from Invitrogen (Carlsbad, CA, USA) and SUM149PT [32] cells were obtained from Asterand Bioscience (Detroit, MI, USA). U2OS ER-mCherry-LacIFokI-DD cells (U2OS-265, referred to in the text as U2OS-FokI) were a kind gift of R. Greenberg (University of Pennsylvania, Philadelphia, PA, USA). All cell lines are routinely authenticated by STR-analysis and tested negative for mycoplasma. 293T, 293 Flp-In, U2OS and RPE1 cells were cultured in high glucose- and GlutaMAX-supplemented DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) + 1% Penicillin / Streptomycin (Thermo Fisher Scientific) and 10% heat inactivated fetal calf serum (Wisent, St-Bruno, Canada) at 37°C, 5% CO₂. SUM149PT cells were cultured in Ham's F12 medium (Gibco) supplemented with 5% FCS, 10 mM HEPES, 1 µg/mL hydrocortisone (Sigma-Aldrich, St. Louis, MI, USA), and 5 µg/mL insulin (Sigma-Aldrich) at 37°C, 5% CO₂. Except for RPE1 clonogenic survival assays, which were performed at 3% O₂, cells were kept under normoxia conditions. Transient transfections of DNA and siRNA were performed using Lipofectamine 2000 (Thermo Fisher Scientific), PEI (Sigma-Aldrich) or calcium phosphate and Lipofectamine RNAiMAX, respectively (Thermo Fisher Scientific). siRNA efficiency was analysed by qPCR and immunoblotting. Stable integration of Flag-C20orf196/FAM35A/REV7 with the Flp-In system was achieved by co-transfection of the pcDNA5-

FRT/TO plasmid with the recombinase vector pOG44 (Thermo Fisher Scientific) and hygromycin selection for integration. Lentiviral particles were produced in 293T cells by co-transfection of the targeting vector with vectors expressing VSV-G, RRE and REV using calcium phosphate or PEI (Sigma-Aldrich). Viral transductions were performed in the presence of 4-8 $\mu\text{g}/\mu\text{L}$ polybrene (Sigma-Aldrich) at an MOI <1, unless stated otherwise. Transduced RPE1 cells were selected by culturing in the presence of 15 $\mu\text{g}/\text{mL}$ puromycin. For the BRCA1-deficient mouse cell experiments, all experiments were performed using virus produced with the LentiCRISPRv2 backbone (see Supplementary Table 5) and cells were infected using polybrene (8 $\mu\text{g}/\text{mL}$). The medium was refreshed after 12 h and transduced cells were selected with puromycin.

The generation of RPE1 hTERT $TP53^{-/-}$ BRCA1-KO Cas9 cells has been described elsewhere [33]. REV7, 53BP1, FAM35A and C20orf196 gene knockouts were generated by electroporation of LentiGuide or LentiCRISPRv2 vectors using a Lonza Amaxa II Nucleofector (Basel, Switzerland) (for sgRNA sequences employed see Supplementary Table 5; REV7 - sgRNA1, FAM35A - sgRNA2 and C20orf196 - sgRNA1 were used for clonal knockout generation). 24 h following transfection, cells were selected for 24-48 h with 15 $\mu\text{g}/\text{mL}$ puromycin, followed by single clone isolation. Triple knockout cell lines of TP53, BRCA1 and 53BP1 were created by mutating BRCA1 from the $TP53^{-/-}$ 53BP1-KO double knockout cell line. Triple knockout cell lines of TP53, BRCA1 and REV7, FAM35A or C20orf196 were created by mutating REV7, FAM35A or C20orf196 in the $TP53^{-/-}$ BRCA1-KO cells. Loss of protein(s) was verified by immunoblotting when antibodies were available. Gene mutations were further confirmed by PCR amplification and TIDE analysis [34] (for primers used for genomic PCR, see Supplementary Table 6, for genomic editing information, see Supplementary Table 2).

To generate SUM149PT 53BP1, PARP1 or C20orf196 knockout populations of cells, SUM149PT-doxCAS9 cells were treated with doxycycline for 24 h at 1 $\mu\text{g}/\text{ml}$ prior to transfection with EditR crRNA (Dharmacon, Lafayette, CO, USA). Transfection of guides 53BP1_5_1, 53BP1_5_3, PARP1_5_2, PARP1_5_4, C20orf196_5-1, C20orf196_5-2, C20orf196_5-3 and C20orf196_5-5 (see Supplementary Table 5) was performed at a concentration of 20 nM (crRNA:tracrRNA) in the presence of doxycycline (1 $\mu\text{g}/\text{ml}$) using Lipofectamine RNAiMAX in 48-well plates (35,000 cells per well). The following day cells were split 1:3, fed 24 h later with media supplemented with 50 nM talazoparib (without doxycycline) and kept in batch culture or further split to generate single cell colonies. Drug-containing media was replenished every 3-4 d until PARP inhibitor resistant pools or clones were established. Clones were subsequently picked, expanded and validated by genomic PCR and sequence analysis (for primers used, see Supplementary Table 6, for genomic editing information, see Supplementary Table 2). Four SUM149PT C20orf196-KO clones with mutations were chosen for further experimentation: clone A (C20orf196 5-1-C1), clone B (C20orf196 5-1-C2), clone C (C20orf196 5-3-C5) and clone D (C20orf196 5-5-C4).

To generate 53BP1-KO double mutant clones, SUM149PT C20orf196 clones A and D were infected with a lentivirus expressing an sgRNA targeting TP53BP1 or a non-targeting control sgRNA (for sequences, see Supplementary Table 5) in media containing 1 µg/ml doxycycline. 48 h after infection, puromycin (1 µg/ml) was added to the media. Selection was maintained for 3 d, until the uninfected control cells were killed. Pools of selection-resistant cells were seeded into 384-well plates for short term survival assays (see below) or subcloned to generate clonal lines.

Mouse ES cells with a selectable conditional *Brca1* deletion (*Rosa26^{CreERT2/wt+};Brca1^{Scd/Δ}*) [35] were cultured on gelatin-coated plates in 60% buffalo red liver (BRL) cell-conditioned medium supplied with 10% fetal calf serum, 0.1 mM β-mercaptoethanol (Merck, Kenilworth, NJ, USA) and 10³ U/ml ESGRO LIF (Millipore, Burlington, MA, USA) under normal oxygen conditions (21% O₂, 5% CO₂, 37 °C).

The KB1P-G3 2D cell line was previously established from a *Brca1*^{-/-} *p53*^{-/-} mouse mammary tumor and cultured as described [16]. Briefly, cells were cultured in DMEM/F-12 medium (Life Technologies, Carlsbad, CA, USA) in the presence of 10% FCS, penicillin/streptomycin (Gibco), 5 µg/mL insulin (Sigma-Aldrich), 5 ng/mL epidermal growth factor (Life Technologies) and 5 ng/mL cholera toxin (Gentaur, Kampenhout, Belgium) under low oxygen conditions (3% O₂, 5% CO₂ at 37 °C).

The KB1P4 3D tumor organoid line was previously established from a *Brca1*^{-/-} *p53*^{-/-} mouse mammary tumor and cultured as described [36]. Cells were seeded in Basement Membrane Extract Type 2 (BME, Trevigen, Gaithersburg, MD, USA) on 24-well suspension plates (Greiner Bio-One, Kremsmünster, Austria) and cultured in AdDMEM/F12 supplemented with 10 mM HEPES (Sigma-Aldrich), GlutaMAX (Invitrogen), penicillin/streptomycin (Gibco), B27 (Gibco), 125 µM N-acetyl-L-cysteine (Sigma-Aldrich), and 50 ng/mL murine epidermal growth factor (Invitrogen).

CH12F3-2 mutant clones were edited either through transient transfection with pX330 plasmid constructs expressing sgRNAs against *Trp53bp1* (sgRNA: *Trp53bp1_e6_834*, see Supplementary Table 5), *Fam35a*, and *Ctc534a2.2* or by lentiviral lentiCRISPR v2 transduction for *C20orf196*. Double knock-out cell lines of *Fam35a* and *Trp53bp1* or *C20orf196* were generated by transient transfection of a pX330 plasmid expressing an sgRNA against *Trp53bp1* or by lentiviral transduction with lentiCRISPRv2 with an sgRNA targeting *C20orf196*.

Antibodies, siRNAs and drugs.

An overview of all the antibodies used in this study, including dilution factors, can be found in Supplementary Table 7. The following siRNAs from Dharmacon were used in this study (final siRNA concentration: 10 or 20nM): 53BP1: siRNA #2 (D-003548-02-0020); RIF1: siGENOME RIF1 siRNA (D-027983-02-0050); REV7: siGENOME MAD2L2 siRNA (M-003272-03-0010); C20orf196: SMARTpool: siGENOME C20orf196 siRNA (M-018767-00-0005); FAM35A: SMARTpool: siGENOME FAM35A siRNA (M-013761-01-0005);

CTC534A2.2 (custom order): siRNA#1: 5'-GGACAAAACUCAAUCAAU-3', siRNA#2: 5'-CAGUAGAUCUAUUGGAGUU-3', siRNA#3: 5'-CUGGAAGACAUUUGGACAA-3', siRNA#4: 5'-GCAAGAUAGUUAAAAGGCA-3' (used as a pool).

The following drugs were used in the course of this study: olaparib (SelleckChem, Houston, TX, USA, or Astra Zeneca, Cambridge, UK), talazoparib (SelleckChem), cisplatin (Sigma-Aldrich), the ATM-inhibitor KU60019 (Sigma-Aldrich), and etoposide (Sigma-Aldrich). Concentration and duration of treatment are indicated in the corresponding figure legends.

Olaparib resistance screens

Viral particles of the TKOv1 sgRNA library were produced as previously described [37]. This library contains 91,320 sgRNA sequences, with a modal number of six sgRNAs per gene. Cas9-expressing cells were infected with an MOI < 0.3 and the coverage of sgRNA representation was maintained at > 100x (SUM149PT) or > 200x (RPE1) (per replicate, if applicable). 24 h following transduction, transduced cells were selected for 120 h with 10 µg/mL puromycin (RPE1) or 48 h with 3 µg/mL puromycin, followed by 72 h with 0.5 µg/mL puromycin (SUM149PT). Three days after transduction, the transduced cells were split into three technical replicates. Cells were passaged once every three days until nine days after infection, at which time olaparib (16 nM for RPE1 *TP53*^{-/-} *BRCA1*-KO, 2 µM for SUM149PT) was added to the cells. Olaparib-containing medium was refreshed every 4 d. Cells were harvested at 3, 9, 18 and 23 d post-infection (RPE1) or at 3, 9, 19 and 26 d post-infection (SUM149PT) for downstream processing as described [37]. In short, total genomic DNA was isolated from 2 × 10⁷ (t3 sample) or 1 × 10⁷ (later time points) cells using the QIAamp DNA Blood Maxi Kit (Qiagen, Germantown, MD, USA). DNA was precipitated with ethanol and sodium chloride and reconstituted in EB buffer (10 mM Tris-HCl pH 7.5). sgRNA sequences were PCR-amplified using primers harbouring Illumina TruSeq adapters with i5 and i7 barcodes, and the resulting libraries were sequenced on a Illumina NextSeq500 (San Diego, CA, USA) using parameters previously described [37]. Analysis was performed using Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGECK) version 0.5.3 [38], in conjunction with Python v3.5.1 on a Mac OS X El Capitan operating system. Non-treated samples collected at day 9 after transduction were compared to treated samples collected at day 23 (RPE1) or day 26 (SUM149PT). The positive score for each gene was calculated by using the 'run' function with the following arguments:

```
MAGECK RUN -L /PATH/TO/TKOV1_LIBRARY/ -N 08-02-2017_141703 --SAMPLE-LABEL  
TEST,CTRL -T 1 -C 0 --FASTQ /PATH/TO/FASTQ1 /PATH/TO/FASTQ2.
```


SUM149PT talazoparib resistance screen

A derivative of SUM149PT with an integrated tetracycline-inducible Cas9 expression allele was lentivirally infected with a genome-wide guide RNA library (“Yusa” library of 90,709 sgRNAs) designed to target 18,010 genes [39], using a multiplicity of infection of 0.3 and infecting >1000 cells per sgRNA. After puromycin selection (3 µg/ml) to remove non-transduced cells, a sample was removed (t0); remaining cells were cultured in the presence or absence of doxycycline plus 100 nM talazoparib, a concentration which normally results in complete inhibition of the cell population. No cells survived in the absence of doxycycline. After two weeks of selection, gDNA from the remaining cells in the doxycycline-treated sample was recovered. The sgRNA sequences from this gDNA were PCR-amplified using barcoded and tailed primers and deep sequenced to identify sgRNAs in the talazoparib-resistant population. sgRNA read data was analysed using a gene-level method (MaGeCK version 0.5.5) as well as using a normalised read frequency method to identify individual sgRNAs associated with resistance, by comparing sgRNA abundances in the resistant and starting populations.

Command used for read count generation:

```
MAGECK COUNT --OUTPUT-PREFIX PREFIX --LIST-SEQ
HUMAN_GENOME_LIBRARY_GUIDES_FOR_MAGECK.CSV --FASTQ T1.FASTQ T0.FASTQ --
SAMPLE-LABEL T1,T0 --TRIM-5 0
```

Command used for MLE analysis:

```
MAGECK MLE --NORM-METHOD NONE --OUTPUT-PREFIX PREFIX --SGRNA-EFF-NAME-
COLUMN 3 --SGRNA-EFF-SCORE-COLUMN 4 --SGRNA-EFFICIENCY
ANNOTATION/SGRNAS.BED --COUNT-TABLE PPTM.COUNTS.TXT --DESIGN-MATRIX
DESIGNMATRIX.TXT
```

IR dropout screen and TKOv2 library

The TKOv2 lentiviral CRISPR library was used for whole-genome CRISPR knockout screening. To design TKOv2, all possible 20mer sequences upstream of NGG PAM sites were collected where the SpCas9 double-strand break would occur within a coding exon (defined by hg19/Gencode v19 “appris_principal,” “appris_candidate_longest,” or “appris_candidate” transcript). Guides with 40-75% GC content were retained and further filtered to exclude homopolymers of length ≥4, SNPs (dbSNP138), and relevant restriction sites, including BsmI (GAATCG) and BsmBI (CGTCTC). Candidate gRNA+PAM sequences were mapped to hg19 and sequences with predicted off-target sites in exons or introns, or sequences with more than two predicted off-target sites (with up to two mismatches) in any location, were discarded. Remaining guides were scored using a “sequence score table” described previously [40]. Four guides per gene were

selected, with a bias toward high sequence scores and maximal coverage across exons (i.e. moderate-scoring guides targeting different exons were preferred to high-scoring guides targeting the same exon). The final library contains 70,555 gRNA targeting 17,942 protein-coding genes, as well as 142 sequences targeting LacZ, luciferase, and eGFP. Oligo sequences were ordered from CustomArray (Bothell, WA), PCR-amplified, and cloned into the pLCKO vector as previously described [37].

hTERT RPE1 *TP53*^{-/-} Cas9-expressing cells were transduced with the lentiviral TKOv2 library (see below) at a low MOI (~0.35) and puromycin-containing media was added the next day to select for transductants. Selection was continued until 72 h post-transduction, which was considered the initial time point, t0. To identify IR sensitizers, the negative-selection screen was performed by subculturing at days 3 and 6 (t3 and t6), at which point the cultures were split into two populations. One was left untreated while the second was treated with 3 Gy of IR using a Faxitron X-ray cabinet (Faxitron, Tucson, AZ, USA) every 3 d after day 6. Cell pellets were frozen at day 18 for gDNA isolation. Screens were performed in technical duplicates and library coverage of ≥375 cells/sgRNA was maintained at every step. gDNA from cell pellets was isolated using the QIAamp Blood Maxi Kit (Qiagen) and genome-integrated sgRNA sequences were amplified by PCR using the KAPA HiFi HotStart ReadyMix (Kapa Biosystems, Wilmington, MA, USA). i5 and i7 multiplexing barcodes were added in a second round of PCR and final gel-purified products were sequenced on Illumina NextSeq500 systems to determine sgRNA representation in each sample. DrugZ [41] was used to identify gene knockouts which were depleted from IR-treated t18 populations but not depleted from untreated cells.

Two-color competitive growth assay

20,000 cells were infected at an MOI of ~1.2 to ensure 100% transduction efficiency with either virus particles of NLS-mCherry LacZ-sgRNA or NLS-GFP GOI-sgRNA. 96 h following transduction, mCherry- and GFP-expressing cells were mixed 1:1 (2,500 cells + 2,500 cells) and plated with or without olaparib (16 nM) or etoposide (100 nM) in 12-well format. During the course of the experiment, cells were subcultured when near-confluency was reached. Olaparib- or etoposide-containing medium was replaced every three days. Cells were imaged for GFP- and mCherry signal the day of initial plating (t=0) and on days 3, 6, 9, 12, 15 and 18 (olaparib), or, in a separate set of experiments, on days 5, 10, 15 and 20 (etoposide). Cells were imaged using the automatic InCell Analyzer (GE Healthcare Life Sciences, Marlborough, MA, USA) with a 4x objective. Segmentation and counting of the number of GFP-positive and mCherry-positive cells was performed using an Acapella script (PerkinElmer, Waltham, MA, USA). Efficiency of indel formation was analysed by performing PCR amplification of the region surrounding the sgRNA sequence and TIDE analysis on DNA isolated from GFP-expressing cells 9 d post-transduction.

Mass spectrometry

Following 24 h of doxycycline-induction of stably integrated 293 FLP-IN cells (expressing Flag, Flag-FAM35A, Flag-REV7, Flag-C20orf196, Flag-CTC-534A2.2), cell pellets from two 150 mm plates were lysed in 50 mM HEPES-KOH (pH8.0), 100 mM KCl, 2 mM EDTA, 0.1% NP-40, 10% glycerol and affinity-purified using Flag-M2 magnetic beads (Sigma-Aldrich). Subsequently, digestion with trypsin (Worthington, Columbus, OH, USA) was performed on-beads. All immunoprecipitations were performed in biological replicates (three for CTC-534A2.2, five for C20orf196 and six for FAM35A and REV7).

For LC-MS/MS analysis, peptides were reconstituted in 5% formic acid and loaded onto a 12-15cm fused silica column with pulled tip packed with C18 reversed-phase material (Reprosil-Pur 120 C18-AQ, 3 μ m, Dr. Maisch, Ammerbuch-Entringen, Germany). Peptides were analysed using an LTQ-Orbitrap Velos (Thermo Scientific) or a 6600 Triple TOF (AB SCIEX, Framingham, MA, USA) coupled to an Eksigent NanoLC-Ultra HPLC system and a nano-electrospray ion source (Proxeon Biosystems, Thermo Fisher Scientific). Peptides were eluted from the column using a 90-100 min gradient of acetonitrile in 0.1% formic acid. Tandem MS spectra were acquired in a data-dependent mode for the top 10 most abundant ions using collision-induced dissociation. After each run, the column was washed extensively to prevent carry-over.

Mass spectrometry data extraction and interaction scoring was performed essentially as described previously [42]. In short, raw mass spectrometry files were converted to mzXML and analyzed using the iProphet pipeline [43], implemented within ProHits [44]. The data were searched against the human and adenovirus complements of the Uniprot (forward and reverse) database (Version 2017_09; reviewed Swiss-Prot entries only), to which common epitope tags were added as well as common contaminants (common contaminants are from the Max Planck Institute, <http://141.61.102.106:8080/share.cgi?ssid=0f2gfuB>, and the Global Proteome Machine, <http://www.thegpm.org/crap/index.html>; 85393 entries were searched). Mascot and Comet search engines were used with trypsin specificity (2 missed cleavages allowed) and deamidation (NQ) and methylation (M) as variable modifications. Charges +2, +3 and +4 were allowed with a parental mass tolerance of maximum 12 ppm and a fragment bin tolerance of 0.6 Da selected for Orbitrap instruments, while 35 ppm and 0.15 Da were allowed for the TripleTOF 6600. For subsequent SAINT analysis (see below), only proteins with an iProphet protein probability ≥ 0.95 were considered, corresponding to an estimated protein false discovery rate (FDR) of $\sim 0.5\%$.

Interactions were analysed with SAINTexpress (v3.6.1) [45, 46]. SAINT probability scores were computed independently for each replicate against eight biological replicate analyses of the negative control (FLAG alone; controls were “compressed” to six virtual controls to increase robustness as described [47]) and the average probability (AvgP) of the best three out of three (CTC534A2.2), five out of five (C20orf196) or six (FAM35A, REV7) biological replicates for each bait was reported as the final SAINT

score. Preys with an estimated FDR $\leq 1\%$ were considered true interactors (AvgP ≥ 0.91). The entire dataset, including the peptide identification and complete SAINTexpress output was deposited as a complete submission in ProteomeXchange through the partner MassIVE housed at the Center for Computational Mass Spectrometry at University of California, San Diego (UCSD; <http://massive.ucsd.edu>). Data are available at MassIVE (<ftp://massive.ucsd.edu/MSV000082207>). Unique accession numbers are MSV000082207 and PXD009313, respectively. Data can also be viewed at the prohits website (prohits-web.lunenfeld.ca) under data set 29: Durocher lab. Data in Fig. 1F is represented using Cytoscape, using analyses with an FDR ≤ 1 or 5 %.

Immunoprecipitation

1×10^7 293T cells were transfected with pcDNA5.1-FRT/TO -FLAG-c20orf196 (10 μg), -GFP-REV7 (2 μg), -V5-CTC534A2.2 (14 μg) and pGLUE-HA-Strep-FAM35A (14 μg) or empty vectors using a standard calcium phosphate or PEI protocol. After 48 h, cells were washed with PBS, scraped, and lysed in 1 ml of lysis buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 2 mM EDTA, 0.5% NP-40, 10mM NaF, 10 mM MgCl_2 and 10 U/ml Benzonase (Sigma-Aldrich)) on ice for 30 min. Lysates were centrifuged at 15,000g for 5 min at 4 °C, and supernatants were incubated with 100 μl of Streptavidin Sepharose High Performance beads (GE Healthcare) or Dynabeads M-280 Streptavidin magnetic beads (Invitrogen) for 1 h at 4 °C. Beads were washed 5 times with lysis buffer and eluted with 10 mM D-biotin (Invitrogen) in lysis buffer for 2 h at 4 °C. When applicable, the eluate was incubated with 20 μl of GFP-Trap_M resin (Chromotek, Planegg-Martinsried, Germany) for 1 h at 4 °C, washed 5 times with lysis buffer and eluted by boiling in sample buffer. Pull-downs and whole cell extracts were loaded onto SDS-PAGE gels, followed by immunoblotting and probing with indicated antibodies. For GFP-CTC534A2.2 immunoprecipitations, an identical GFP-Trap pulldown procedure as above was used. For V5-CTC534A2.2 immunoprecipitations, lysates from one confluent 10-cm dish of 293T cells transfected with 10 μg pcDNA5.1-FRT/TO-V5-CTC534A2.2 vector was incubated with 10 $\mu\text{g}/\text{ml}$ anti-V5 antibody (Invitrogen) for 2 hours at 4 °C. Subsequently 50 μl of protein G Dynabeads (Invitrogen) was added to the lysates and incubated for an additional 1 h at 4 °C. Beads were washed 4 times with lysis buffer and boiled in 50 μl 2xSDS buffer.

Clonogenic survival assays

RPE1-hTERT *TP53*^{-/-} cells were seeded in 10-cm dishes (WT: 250 cells; *BRCA1*-KO 53BP1-KO, 500 cells; *BRCA1*-KO or *BRCA1*-KO *C20orf196*-KO: 1,500 cells; *BRCA1*-KO *FAM35A*-KO: 750 cells) in the presence of 800 nM cisplatin or 16 nM olaparib or left untreated. Cisplatin dosing lasted 24 h, after which cells were grown in drug-free medium. Olaparib-containing medium was refreshed after 7 d. After 14 d, colonies were stained with crystal

violet solution (0.4 % (w/v) crystal violet, 20% methanol) and manually counted. Relative survival was calculated for the drug treatments by setting the number of colonies in non-treated controls at 100%.

For *Rosa26^{CreERT2/wt} Brca1^{SCo/Δ}* cells, Cre-mediated inactivation of the endogenous mouse *Brca1*SCo allele was achieved by overnight incubation of cells with 0.5 μM 4-hydroxytamoxifen (Sigma-Aldrich). Four days after switching, cells were seeded in triplicate at 10,000 cells per well in 6-well plates for clonogenic survival assays. For experiments with *Rosa26^{CreERT2/wt} Brca1^{SCo/Δ} p53*-null cells, cells were plated in the presence of 15 nM olaparib. Cells were stained with 0.1% crystal violet one week later. Clonogenic survival assays with PARPi (olaparib) and ATMi (KU60019) combination treatment were performed as described previously with minor adjustments [42].

5 × 10³ KB1P-G3 cells were seeded per well into 6-well plates on day 0, and then PARPi, ATMi, both or neither were added. The medium was refreshed every 3 d. On day 6, the ATMi alone and untreated groups were stopped and stained with 0.1% crystal violet, the other groups were stopped and stained on day 9. Plates were scanned with a GelCount (Oxford Optronics, Abingdon, UK). Quantifications were performed by solubilizing the retained crystal violet using 10% acetic acid and measuring the absorbance at 562 nm using a Tecan plate reader (Tecan, Männedorf, Switzerland).

Short term survival assays

10,000 RPE1-hTERT Cas9 *TP53*^{-/-} parental cells and additional mutants (*BRCA1*-KO and/or *FAM35A*-KO) with or without stable integration of indicated eGFP-fusions by viral transduction were seeded in 12-well format with or without 200 nM olaparib (and 1 μg/mL doxycycline if applicable). Medium with olaparib (and doxycycline) was replaced after 4 d, and cells were trypsinized and counted after seven days using an automated Z2 Coulter Counter analyzer (Beckman Coulter, Indianapolis, IN, USA).

SUM149PT cells were plated at 500 cells per well in 384-well plates and varying amounts of talazoparib in DMSO were added the following day using an Echo 550 liquid handler (Labcyte, San Jose, CA, USA). After 5 d of growth, cell survival was assayed using CellTiter-Glo according to the manufacturer's protocol (Promega, Madison, WI, USA).

Immunofluorescence

For 53BP1 immunofluorescence (IF), cells were cultured on coverslips and treated with 5 or 10 Gy X-irradiation and fixed with 2-4% paraformaldehyde (PFA) 1 h after irradiation. Cells were permeabilized with 0.3% Triton X-100, followed by blocking in 10% goat serum, 0.5% saponin, 0.5% NP-40 in PBS (blocking buffer A). Cells were co-stained using 53BP1 and γH2AX primary antibodies (see Supplementary Table 7) in blocking buffer A for 1.5 h at room temperature, followed by 4 washes in PBS, incubation with appropriate secondary

antibodies in blocking buffer A plus 0.8 $\mu\text{g}/\text{mL}$ DAPI for 1.5 h at room temperature, and finally four washes in PBS.

For RAD51 IF, cells with or without stable integration of eGFP-tagged proteins or sgRNAs via viral transduction were grown on glass coverslips and treated with 10 Gy X-irradiation and recovered for 3 to 6 h (as indicated). Cells were fixated and extracted using 1% PFA, 0.5% Triton X-100 in PBS for 20 min at room temperature, followed by a second extraction/fixation using 1% PFA, 0.3% Triton X-100, 0.5% methanol in PBS for 20 min at room temperature. Blocking, primary and secondary antibody incubations (1.5 h at room temperature followed by 4 PBS washes) were performed in BTG buffer (10 mg/mL BSA, 0.5% Triton X-100, 3% goat serum, 1 mM EDTA in PBS) or PBS⁺ (0.5% BSA, 0.15% glycine in PBS).

For REV7 and RIF1 IF, cells were grown on glass coverslips, treated with 5 or 10 Gy X-irradiation and fixed with 2-4% PFA 1-2 h after irradiation. Cells were permeabilized with 0.3% Triton X-100. For REV7 blocking, primary and secondary antibody incubations (1.5 h at room temperature followed by 4 washes in PBS) were performed in blocking buffer A. For RIF1 blocking, primary and secondary antibody incubations (1.5 h at room temperature followed by 4 washes) were performed in PBG buffer (0.2% cold water fish gelatin (Sigma Aldrich), 0.5% BSA in PBS).

For GFP-Shieldin focus and laser stripe analysis, U2OS or RPE1 cells were grown on glass coverslips and either transiently transfected with 1 μg vector expressing GFP-FAM35A or -CTC534A2.2, or virally transduced with GFP-FAM35A-expressing vector. 48 h post transfection, or 24 h post 0.5 $\mu\text{g}/\text{mL}$ doxycyclin induction, cells were treated with 5 Gy X-irradiation or micro-irradiated, pre-extracted 10 min on ice with NuEx buffer (20 mM HEPES, pH 7.4, 20 mM NaCl, 5 mM MgCl₂, 0.5% NP-40, 1 mM DTT and protease inhibitors) followed by 10 min 2% PFA fixation 1 h post-IR/micro-irradiation. Antibody staining and blocking were performed as described above except in PBS + 0.1% Tween-20 + 5% BSA using GFP and γH2AX antibodies. 0.8 $\mu\text{g}/\text{mL}$ DAPI was included in all experiments to stain nuclear DNA. Coverslips were mounted using Prolong Gold mounting reagent (Invitrogen) or Aqua PolyMount (Polyscience, Warrington, PA, USA). Images were acquired using a Zeiss LSM780 laser-scanning microscope (Oberkochen, Germany), a Leica SP8 confocal microscope (Wetzlar, Germany) or a Zeiss AxioImager D2 widefield fluorescence microscope. Foci were manually counted.

RAD51 immunofluorescence in KB1P-G3 cells was performed as described previously, with minor modifications [11]. Cells were grown on 8-well chamber slides (Millipore). Ionizing-radiation induced foci were induced by γ -irradiation (10 Gy) 4 h prior to sample preparation. Cells were then washed in PBS⁺⁺ (2% BSA, 0.15% glycine, 0.1% Triton X-100) and fixed with 2% PFA/PBS⁺⁺ for 20 min on ice. Fixed cells were washed with PBS⁺⁺ and were permeabilized for 20 min in 0.2% Triton X-100/PBS⁺⁺. All subsequent steps were performed in PBS⁺⁺. Cells were washed three times and blocked for 30 min at room temperature, incubated with the primary antibody for 2 h at RT, washed thrice and incubated with the secondary antibody for 1 h at room temperature. Lastly, cells were

mounted and counterstained using Vectashield mounting medium with DAPI (H1500, Vector Laboratories, Burlingame, CA, USA).

Scale bars indicated in the figure panels represent 10 μm , unless stated otherwise.

LacR-RIF1-N-terminus and FokI-induced focus formation

For monitoring recruitment of GFP-tagged Shieldin subunits to mCherry-LacR-Rif1(1-967) foci, 150,000 U2OS-FokI cells (known also as U2OS-DSB) [48] were seeded on 6-well plates containing glass coverslips without any induction of FokI. 24 h after seeding, cells were transfected using 1 μg of pDEST-mCherry-LacR or pDEST-mCherry-LacR-Rif1(1-967), if applicable, and 0.5-1 μg of GFP fusion expression vectors. Cells were fixed with 4% PFA 24-48 h after transfection. For monitoring the localization of the FAM35A N-terminus to Rif1(1-967) foci with siRNA knockdown of other Shieldin subunits, an essentially identical protocol was used with the following adjustments: 350,000 U2OS-FokI cells were reverse-transfected with Lipofectamine RNAiMAX-siRNA (10 nM) complex. 24 h after siRNA transfection, the mCherry-LacR and GFP fusion plasmids were transfected. Cells were fixed with 4% PFA 48 h after DNA transfection. For monitoring recruitment of GFP-tagged Shieldin subunits to DSBs at the LacO array, FokI stabilization and nuclear translocation was induced by treating cells with 0.1 μM Shield1 (Clontech, Mountain View, CA, USA) and 10 $\mu\text{g}/\text{mL}$ hydroxytamoxifen for 4 h.

ImageJ (<https://imagej.nih.gov/ij/>) was used to quantify foci in the U2OS-FokI system. An mCherry focus and DAPI nuclear signal were used to generate masks. The average GFP fluorescence or immunofluorescence intensity in the mCherry focus mask was divided by the corresponding average nuclear intensity, and the ratio is reported. Cells displaying a ratio of focus/nuclear average intensity >3 are defined as containing a focus.

Microirradiation

For laser microirradiation, virally transduced RPE1 cells expressing the indicated eGFP-tagged proteins were grown on glass coverslips and transfected with siRNAs. 48 h post-transfection, protein expression was induced using 0.5 $\mu\text{g}/\text{mL}$ doxycycline, and 24 h later cells were presensitized with 1 $\mu\text{g}/\text{mL}$ Hoechst for 15 min at 37 $^{\circ}\text{C}$. DNA damage was introduced with a 355 nm laser (Coherent, Santa Clara, CA, USA, 40mW) focused through a Plan-Apochromat 40x oil objective to yield a spot size of 0.5-1 mm using a LSM780 confocal microscope (Zeiss) and the following laser settings: 100% power, 1 iteration, frame size 128 x 128, line step 7, pixel dwell: 25.21 μs .

Traffic light reporter assay

Cells were infected with pCVL.TrafficLightReporter.Ef1a.Puro lentivirus at a low MOI (0.3-0.5) and selected with puromycin (15 $\mu\text{g}/\mu\text{l}$). 7×10^5 cells were nucleofected with

5 µg of pCVL.SFFV.d14GFP.Ef1a.HA.NLS.Sce(opt).T2A.TagBFP plasmid DNA in 100 µL of electroporation buffer (25 mM Na₂HPO₄ pH 7.75, 2.5 mM KCl, 11 mM MgCl₂), using program T23 on a Nucleofector 2b (Lonza). After 72 h, GFP and mCherry fluorescence was assessed in BFP-positive cells using a Fortessa X-20 (BD Biosciences, San Jose, CA, USA) flow cytometer.

Phospho-RPA immunoblotting

For phospho-RPA staining, CH12 cells were left untreated, or were treated with 25 Gy of ionizing radiation using a Faxitron X-ray cabinet, and were then collected by centrifugation 3 h later. Pellets were lysed on ice for 10 min in high salt lysis buffer (50 mM Tris-HCl pH 7.6, 300 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM DTT, 1x EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland)), cleared by centrifugation at 20,000 x g for 10 min at 4 °C, and quantified by bicinchoninic acid assay (BCA; Pierce, Thermo Fisher Scientific). Equal amounts of whole-cell extracts were separated by SDS-PAGE on 4-12% Bis-Tris gradient gels (Invitrogen), transferred to nitrocellulose and immunoblotted for pRPA32 (S4/S8).

Mouse mammary tumour models

All animal experiments were approved by the Animal Ethics Committee of The Netherlands Cancer Institute (Amsterdam, the Netherlands) and performed in accordance with the Dutch Act on Animal Experimentation (November 2014). KB1P4 tumor organoids were transduced using spinoculation as described previously [49]. NMRI-nude female mice were purchased from Janvier Laboratories and used for transplantation studies at the age of 6-9 weeks. A power analysis was performed to calculate that a minimum of 8 mice per group were needed to achieve a power of 0.8 (two-sided test, alpha=0.05). Tumor organoids were allografted in mice as described previously with minor adjustments [35]. Briefly, tumor organoids were collected, incubated with TripLE at 37 °C for 5 min, dissociated into single cells, washed and embedded in a 1:1 mixture of tumor organoid culture medium and Basement Membrane Extract (Trevigen) in a cell concentration of 10⁴ cells per 40 µL. Subsequently, 10⁴ cells were injected in the fourth right mammary fat pad of NMRI nude mice. Mammary tumor size was determined by caliper measurements and tumor volume was calculated (0.5 x length x width²). Treatment of tumor-bearing mice was initiated when tumors reached a size of 50-100 mm³. Mice were randomly allocated into the untreated (n = 8) or olaparib treatment group (n = 8). Olaparib was administered in a blinded fashion at 100 mg/kg intraperitoneally for 80 consecutive days. Animals were sacrificed with CO₂ when the tumor reached a volume of 1,500 mm³. The tumor was collected, fixed in formalin for histology and several tumor pieces were harvested for DNA analysis.

Class switch recombination assays

To induce switching in CH12F3-2 murine B cell lymphoma cells, 2×10^5 cells were cultured in CH12 media supplemented with a mixture of IL4 (10 ng/mL, R&D Systems #404-ML-050, Minneapolis, MN, USA), TGF β (1 ng/mL, R&D Systems #7666-MB-005) and anti-CD40 antibody (1 μ g/mL, #16-0401-86, eBioscience, Thermo Fisher) for 48 h. Cells were then stained with anti-IgA-PE and fluorescence signal was acquired on an LSR II or Fortessa X-20 flow cytometer (BD Biosciences). To probe AID levels in the stimulated cells, immunoblotting was performed on total cell lysates using anti-AID and anti- β -actin antibodies (Supplementary Table 7). Band quantification was analysed by ImageJ.

Plasmid integration assay

200,000 RPE1 cells were seeded into 6-well plates and 24 h later transfected with 2 μ g of BamHI/EcoRI-linearized pGFP-c1 using PEI. 72 h post-transfection, cells were seeded for colony formation into 10 cm dishes in the presence (50,000 cells per dish) or absence (500 cells per dish) of 600 μ g/mL G418. At this point, transfection efficiency was analysed by measuring GFP-positivity using flow cytometry. Medium with G418 was refreshed every 3 d. 14 d after seeding, colonies were stained with crystal violet solution and manually counted. NHEJ efficiency was calculated according to the following formula:

$$\frac{\% \text{SURVIVING COLONIES ON SELECTION}}{(\% \text{OF SURVIVING COLONIES WITHOUT SELECTION}) * (\% \text{OF TRANSFECTED CELLS})}$$

The data shown for the different KO clones in Supplementary Fig. S8E is representing NHEJ efficiency as calculated with the above formula, followed by normalisation to WT cells (for which NHEJ efficiency is set to 100%).

DNA binding assays

Shieldin proteins were isolated using the immunoprecipitation protocol described above with the following modifications. 293T cells were transfected with pGLUE-FAM35A(421-904), the indicated mutants of this construct, or the empty pGLUE Strep/HA-tagging vector and pcDNA5.1-FRT/TO -FLAG-C20orf196 in a 2:1 ratio for a total of 10 μ g per 10 cm dish. Complexes were immunoprecipitated as described, except using a reduced NP-40 detergent concentration (0.1%) for the last two washes and elution buffer. Eluted proteins were concentrated using Amicon Ultra 0.5 ml 10K centrifugal filter units (Millipore). Concentrations of isolated proteins were estimated by SDS-PAGE and Coomassie staining, followed by comparison to a standard curve of known bovine serum albumin (BSA) concentrations measured by fluorescence in the 700 nm channel of the Odyssey imager (LI-COR). A radiolabeled ssDNA probe was

prepared by T4 polynucleotide kinase (New England Biolabs, Ipswich, MA, US) phosphorylation of HPLC-purified 59-nt DNA oligo (BioBasic, Markham, ON, CA; TACGT-TAGTATGCGTTCTTCCTCCAGAGGTT) using [γ - 32 P]-ATP (3000 Ci/mmol, 10 mCi/ml; Perkin-Elmer, Woodbridge, ON, CA). Unlabeled competitors were prepared using the same oligo sequence alone or hybridized to the complementary sequence (AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACCTCTGGAAGGAAGAACGCATACTAACGTA) by heating at 80 °C for 10 mins and gradual cooling to room temperature overnight.

For electrophoretic mobility shift assays, 20 nM of labeled ssDNA probe was incubated with purified proteins for 20 min in the elution buffer with the addition of 1 mM DTT and 1 mg/ml BSA at room temperature. Glycerol was then added to a final concentration of 8.3% and resolved on 6% acrylamide-TAE gels. Gels were adhered onto blotting paper (VWR) and enclosed in plastic wrap. Gels were exposed to a storage phosphor screen (GE Healthcare) and visualized using a Typhoon FLA 9500 biomolecular imager (GE Healthcare). Dissociation constant (K_d) was determined in GraphPad Prism from nonlinear regression analysis assuming single-site specific binding of saturation titration experiments, defining all signal above the free probe band to be bound probe, as measured in ImageQuant TL (GE Healthcare). The fraction of probe bound is defined as:

$$\text{SIGNAL OF BOUND PROBE} / (\text{SIGNAL OF BOUND PROBE} + \text{SIGNAL OF FREE PROBE})$$

and the concentration of unbound FAM35AC-C20orf196 (referred in the text as SHLD2C-SHLD1) complex is calculated by multiplying the fraction of probe bound by the initial concentration of ssDNA probe, and subtracting this from the initial concentration of SHLD2C-SHLD1, given the assumption of 1:1 binding.

Statistical analysis

All data is represented as individual replicates and replicate number, mean and error bars are explained in the figure legends. Used statistical tests (all common tests) and resulting p-values are indicated in the figure legends and/or figure panels and have been generated using GraphPad Prism software.

Data availability statement

All source data represented in the graphs displayed in this article are available online (Supplementary Data files 1-12). Uncropped Western blots can be found online as Supplementary Figure 1. Data of the CRISPR Cas9 screens are included as Supplementary Table 1 (PARPi positive selection screens) or Supplementary Table 4 (IR sensitivity dropout screen). IP-MS data (Supplementary Table 3) are available at MassIVE (<ftp://>

massive.ucsd.edu/MSV000082207, with unique accession numbers MSV000082207 and PXD009313). IP-MS data can also be viewed at the prohits website (prohits-web.lunenfeld.ca) under data set 29: Durocher lab.

Acknowledgements

We thank J. Young (Repare Therapeutics), M. Bashkurov (NBCC, LTRI), L. Kesselman (LTRI), S. Rossi (LTRI) and M. Rother (LUMC). We thank R. Greenberg (U Penn) for the U2OS-FokI cells. The authors acknowledge that J. Lukas first proposed the name Shieldin. SN is funded by a research fellowship from the Dutch Cancer Society (KWF). SAd is a Banting Post-Doctoral Fellow. DS is funded by a post-doctoral research fellowship from CIHR. HvA is funded by the European Research Council (CoG-50364). TH is supported by MD Anderson Cancer Center Support Grant P30 CA016672 and the Cancer Prevention Research Institute of Texas (CPRIT/RR160032). Work in the AM lab is funded through CIHR grant PJT153307. ACG is funded by CIHR grant FDN143301. Work in the CJL lab is funded by Programme Grants from Cancer Research UK (CRUK/A14276) and Breast Cancer Now (CTR-Q4-Y2). Work in the SR and JJ labs is funded by the Dutch Cancer Society (KWF 2014-6532), the Netherlands Organization for Scientific Research (VICI 91814643 and a National Roadmap grant for Large-Scale Research Facilities to JJ), the Swiss National Science Foundation (310030_156869 to SR), the European Research Council (CoG-681572 to SR and SyG-319661 to JJ). DD and ACG are Canada Research Chairs (Tier I). DD is funded by CIHR grant FDN143343, Canadian Cancer Society (CCS grant #705644) and OICR grant OICR-OC-TRI.

Author Contributions

SMN initiated the project in the DD lab, performed the RPE1 BRCA1-KO screen, validated hits and performed functional follow up. SAd performed validation and localization studies. DS carried out structure-function analyses and DNA binding studies. MB performed murine tumor model studies. SJP analyzed the SUM149PT talazoparib screen and validated hits. AL generated knockouts in CH12F3-2 cells, carried out CSR assays and analyzed AID levels. MO performed the IR screen and validation. AAQ carried out immunopurifications and helped with IF quantitation. NM performed CSR, TLR and pRPA assays. MZ carried out the SUM149PT olaparib screen and generated the RPE1 BRCA1-KO cells. SAn examined *Shld1* and *Shld2* mutations in mES cells. DK, IB, FS, JF and RB performed the SUM149PT talazoparib screen and validation. IB and FS developed SUM149PT knockout cells. FS carried out SUM149PT epistasis experiments. AS performed the REV7 IP-MS. SL initiated work on REV7. RKS generated vectors and edited the manuscript. MMM generated IP-MS cell lines. AMc carried out screen analysis, cloning and TIDE. TGR performed Shieldin qPCR. ZYL carried out IP-MS for SHLD1-3 under supervision of ACG. TH analyzed screen data and built the TKOv2 library with JM. AMa

supervised AL. JJ and SR supervised MB and SAN. DD and HvA supervised SMN. CJL supervised SJP, DK, FS, IB, JF and RB. SMN and DD wrote the manuscript with input from the other authors.

Disclosure of Potential Conflicts of Interest

DD and TH are advisors to Repare Therapeutics. CJL is a named inventor on patents describing the use of PARP inhibitors (DK3044221 (T3), ES2611504 (T3), US2014378525 (A1), WO2008020180 (A2), WO2009027650 (A1)) and stands to gain from their use as part of the ICR “Rewards to Inventors” scheme.

References


1. Hustedt N, Durocher D. The control of DNA repair by the cell cycle. *Nature Cell Biology*. 2017; 19: 1-9.
2. Panier S, Boulton SJ. Double-strand break repair: 53BP1 comes into focus. *Nat Rev Mol Cell Biol*. 2014; 15: 7-18.
3. Munoz IM, Jowsey PA, Toth R, Rouse J. Phospho-epitope binding by the BRCT domains of hTIP controls multiple aspects of the cellular response to DNA damage. *Nucleic Acids Res*. 2007; 35: 5312-22.
4. Callen E, Di Virgilio M, Kruhlak MJ, Nieto-Soler M, Wong N, Chen HT, et al. 53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. *Cell*. 2013; 153: 1266-80.
5. Chapman JR, Barral P, Vannier JB, Borel V, Steger M, Tomas-Loba A, et al. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. *Mol Cell*. 2013; 49: 858-71.
6. Di Virgilio M, Callen E, Yamane A, Zhang W, Jankovic M, Gitlin AD, et al. Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching. *Science*. 2013; 339: 711-5.
7. Escribano-Díaz C, Orthwein A, Fradet-Turcotte A, Xing M, Young JT, Tkáč J, et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. *Mol Cell*. 2013; 49: 872-83.
8. Feng L, Li N, Li Y, Wang J, Gao M, Wang W, et al. Cell cycle-dependent inhibition of 53BP1 signaling by BRCA1. *Cell Discov*. 2015; 1: 15019.
9. Zimmermann M, Lottersberger F, Buonomo SB, Sfeir A, de Lange T. 53BP1 regulates DSB repair using Rif1 to control 5' end resection. *Science*. 2013; 339: 700-4.
10. Boersma V, Moatti N, Segura-Bayona S, Peuscher MH, van der Torre J, Wevers BA, et al. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5' end resection. *Nature*. 2015; 521: 537-40.
11. Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. *Nature*. 2015; 521: 541-4.
12. Adkins NL, Niu H, Sung P, Peterson CL. Nucleosome dynamics regulates DNA processing. *Nat Struct Mol Biol*. 2013; 20: 836-42.
13. Fradet-Turcotte A, Canny MD, Escribano-Díaz C, Orthwein A, Leung CC, Huang H, et al. 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. *Nature*. 2013; 499: 50-4.
14. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. *Nat Struct Mol Biol*. 2010; 17: 688-95.
15. Bunting SF, Callén E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. *Cell*. 2010; 141: 243-54.
16. Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. *Cancer Discov*. 2013; 3: 68-81.
17. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. *Science*. 2017; 355: 1152-8.


18. Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. *Nat Commun.* 2018; 9: 1849.
19. Hanafusa T, Habu T, Tomida J, Ohashi E, Murakumo Y, Ohmori H. Overlapping in short motif sequences for binding to human REV7 and MAD2 proteins. *Genes Cells.* 2010; 15: 281-96.
20. Hutchins JR, Toyoda Y, Hegemann B, Poser I, Hériché JK, Sykora MM, et al. Systematic analysis of human protein complexes identifies chromosome segregation proteins. *Science.* 2010; 328: 593-9.
21. Maréchal A, Zou L. RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response. *Cell Res.* 2015; 25: 9-23.
22. Baumann P, Price C. Pot1 and telomere maintenance. *FEBS Lett.* 2010; 584: 3779-84.
23. Kuhar R, Gwiazda KS, Humbert O, Mandt T, Pangallo J, Brault M, et al. Novel fluorescent genome editing reporters for monitoring DNA repair pathway utilization at endonuclease-induced breaks. *Nucleic Acids Res.* 2014; 42: e4.
24. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. *Proc Natl Acad Sci U S A.* 2007; 104: 12111-6.
25. Nakamura M, Kondo S, Sugai M, Nazarea M, Imamura S, Honjo T. High frequency class switching of an IgM+ B lymphoma clone CH12F3 to IgA+ cells. *Int Immunol.* 1996; 8: 193-201.
26. Luijsterburg MS, de Krijger I, Wiegant WW, Shah RG, Smeenk G, de Groot AJL, et al. PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining. *Mol Cell.* 2016; 61: 547-62.
27. Mirman Z, Lottersberger F, Takai H, Kibe T, Gong Y, Takai K, et al. 53BP1–RIF1–shieldin counteracts DSB resection through CST- and Pol α -dependent fill-in. *Nature.* 2018; 560: 112-6.
28. Fan J, Pavletich NP. Structure and conformational change of a replication protein A heterotrimer bound to ssDNA. *Genes Dev.* 2012; 26: 2337-47.
29. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. *Nat Methods.* 2014; 11: 783-4.
30. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science.* 2014; 343: 84-7.
31. Olhovskiy M, Williton K, Dai AY, Pasculescu A, Lee JP, Goudreaux M, et al. OpenFreezer: a reagent information management software system. *Nat Methods.* 2011; 8: 612-3.
32. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. *Cancer research.* 2006; 66: 41-5.
33. Zimmermann M, Murina O, Reijns MAM, Agathangelou A, Challis R, Tarnauskaitė Ž, et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. *Nature.* 2018; 559: 285-9.
34. Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res.* 2014; 42: e168.
35. Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijin CN, Prasetyanti P, et al. A high-throughput functional complementation assay for classification of BRCA1 missense variants. *Cancer Discov.* 2013; 3: 1142-55.
36. Duarte AA, Gogola E, Sachs N, Barazas M, Annunziato S, J RdR, et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. *Nat Methods.* 2018; 15: 134-40.
37. Hart T, Chandrashekar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. *Cell.* 2015; 163: 1515-26.
38. Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. *Genome Biol.* 2014; 15: 554.
39. Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. *Cell Rep.* 2016; 17: 1193-205.
40. Hart T, Tong AHY, Chan K, Van Leeuwen J, Seetharaman A, Aregger M, et al. Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens. *G3 (Bethesda).* 2017; 7: 2719-27.
41. Wang G, Zimmermann M, Mascall K, Lenoir WF, Moffat J, Angers S, et al. Identifying drug-gene interactions from CRISPR knockout screens with drugZ. *bioRxiv.* 2017: 232736.

42. Tkáč J, Xu G, Adhikary H, Young JTF, Gallo D, Escribano-Díaz C, et al. HELB Is a Feedback Inhibitor of DNA End Resection. *Mol Cell*. 2016; 61: 405-18.
43. Shteynberg D, Deutsch EW, Lam H, Eng JK, Sun Z, Tasman N, et al. iProphet: multi-level integrative analysis of shotgun proteomic data improves peptide and protein identification rates and error estimates. *Mol Cell Proteomics*. 2011; 10: M111.007690.
44. Liu G, Zhang J, Larsen B, Stark C, Breitkreutz A, Lin ZY, et al. ProHits: integrated software for mass spectrometry-based interaction proteomics. *Nat Biotechnol*. 2010; 28: 1015-7.
45. Choi H, Larsen B, Lin ZY, Breitkreutz A, Mellacheruvu D, Fermin D, et al. SAINT: probabilistic scoring of affinity purification-mass spectrometry data. *Nat Methods*. 2011; 8: 70-3.
46. Teo G, Liu G, Zhang J, Nesvizhskii AI, Gingras AC, Choi H. SAINTexpress: improvements and additional features in Significance Analysis of INteractome software. *J Proteomics*. 2014; 100: 37-43.
47. Mellacheruvu D, Wright Z, Couzens AL, Lambert JP, St-Denis NA, Li T, et al. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. *Nat Methods*. 2013; 10: 730-6.
48. Tang J, Cho NW, Cui G, Manion EM, Shanbhag NM, Botuyan MV, et al. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. *Nat Struct Mol Biol*. 2013; 20: 317-25.
49. Koo BK, Stange DE, Sato T, Karthaus W, Farin HF, Huch M, et al. Controlled gene expression in primary Lgr5 organoid cultures. *Nat Methods*. 2011; 9: 81-3.
50. Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, et al. Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. *Molecular cancer therapeutics*. 2017; 16: 2022-34.


Supplementary Figures and Tables

SUPPLEMENTARY FIGURE S1 | Supporting data for the identification of the Shieldin complex and its role in the response to genotoxic treatments. (A) Schematic of the PARPi resistance screens. (B) Competitive growth assays determining the capacity of the indicated sgRNAs to cause resistance to PARP inhibitors in RPE1 BRCA1-KO cells. Data is presented as the mean fraction of GFP-positive cells \pm SEM, normalized to day 0 ($n = 3$, independent viral transductions). Gene editing efficiencies of the sgRNAs can be found in Supplementary Table 2. Note that we have not been able to obtain TIDE data for the *ATMIN*-targeting sgRNAs. (C) Representative images of SUM149PT-Cas9 cells transfected with indicated crRNAs (see Methods) and exposed to 50 nM talazoparib for 14 d. Purple coloration indicates cells detected by Incucyte live-cell imaging. Scale bar represents 100 μ m. The data is a representative set of images from two biologically independent experiments. (D) Screenshot of the genomic locus surrounding human CTC-534A2.2 taken from ENSEMBL. (E) Schematic of the screen performed in RPE1-hTERT *TP53*^{-/-} cells stably expressing Cas9 to study genes mediating IR-sensitivity. (F-G) Competitive growth assays measuring the capacity of the indicated sgRNAs to cause resistance to etoposide (100 nM) in RPE1 WT cells (F) or PARP inhibitors (16 nM) in RPE1 BRCA1-KO cells (G). Data is presented as the mean fraction of GFP-positive cells \pm SD, normalized to day 0 ($n = 3$, independent viral transductions). Gene editing efficiencies of the sgRNAs can be found in Supplementary Table 2. (H) Talazoparib sensitivity in 11 SHLD1-KO SUM149PT clones obtained after co-transfection of tracrRNA and one of four distinct SHLD1 crRNAs (5-1, 5-2, 5-3 or 5-5). Each clone was exposed to talazoparib in a 384-well plate format for five days. As a comparison, talazoparib sensitivity in parental SUM149PT cells with WT SHLD1 (WT) is shown, as is talazoparib resistance in a BRCA1 revertant subclone (BRCA1-rev) of SUM149PT [50]. Bars represent the mean \pm SD ($n=4$ biologically independent experiments). ANOVA was performed for each SHLD1-KO clone vs. WT using Dunnett correction for multiple comparisons, $p < 10^{-15}$. Gene editing efficiencies can be found in Supplementary Table 2. (I) BRCA1-KO and BRCA1-KO/SHLD2-KO cells were virally transduced with expression vectors for GFP alone or GFP-SHLD2. Sensitivity to olaparib (200 nM) was determined by a short-term survival assay in the presence of 1 μ g/mL doxycycline to induce protein expression. Data is represented as dots for every individual experiment with the bar representing the mean \pm SD ($n=3$).






SUPPLEMENTARY FIGURE S2 | Supporting data that Shieldin inhibits HR. (A) Representative micrographs of RAD51 focus formation in the indicated RPE1 cell lines (data quantitated in Fig. 2D, $n \geq 3$). (B) Traffic light reporter (TLR) assay testing RPE1 BRCA-KO cells virally transduced with sgRNAs targeting 53BP1 or SHLD3. Data is represented as dots for individual experiments with the bar representing the mean \pm SD ($n=3$). Gene editing efficiencies of the sgRNAs can be found in Supplementary Table 2). (C) Representative flow cytometry plots of cells analysed with the TLR assay (data quantitated in Fig. 2E, $n \geq 3$). (D) Representative flow cytometry plots of cells analysed with the TLR assay (data quantitated in Supplementary Fig. S2B).



SUPPLEMENTARY FIGURE S3 | Supporting data that mouse Shieldin promotes resistance to PARP inhibition in *Brca1*-mutated cells and tumours.


(A) Clonogenic survival assays of transduced KB1P-G3 cells treated with indicated olaparib doses \pm ATM inhibitor (ATMi) KU60019 (500 nM). On day 6, the ATMi alone and untreated groups were stopped and stained with 0.1% crystal violet; the other groups were stopped and stained on day 9. Data shown is a representative set from 3 biologically independent experiments (with 3 technical replicates each). (B) Left, quantitation of Rad51 focus formation in parental KB1P-G3 (*Brca1*^{-/-}; *Trp53*^{-/-}) cells or KB1P-G3 cells that were transduced with the indicated lentiviral sgRNA vectors. Cells were fixed without treatment or 4 h after irradiation (10 Gy dose). Each data point represents a microscopy field containing a minimum of 50 cells; the bar represents the mean \pm SD (n=15). Right, representative micrographs of Rad51-negative and -positive cells (the latter is indicated by an arrowhead). DNA was stained with DAPI. (C) Clonogenic survival assay of *Rosa26*^{CreERT2/wt}; *Brca1* ^{$\Delta\Delta$} ; *p53*-null mES-cells virally transduced with the indicated sgRNA and treated without or with 15 nM olaparib for 7 d. Gene editing efficiencies of the sgRNAs can be found in Supplementary Table 2. Data shown is a representative set from 3 biologically independent experiments (with \geq 2 technical replicates each). (D) Clonogenic survival assay of *Rosa26*^{CreERT2/wt}; *Brca1*^{*Scd4*} mES-cells virally transduced with the indicated sgRNA and treated without or with 0.5 μ M tamoxifen to induce BRCA1 depletion. Gene editing efficiencies of the sgRNAs can be found in Supplementary Table 2. Data shown is a representative set from 2 biologically independent experiments (with 3 technical replicates each).



SUPPLEMENTARY FIGURE S4 | Supporting data that Shieldin localizes to DSB sites

(A) Representative micrographs of the experiments quantitated in Fig. 3C. (B) Representative micrographs of the experiments quantitated in Fig. 3E. (C) Quantitation of mRNAs for *SHLD1*, *SHLD2* and *SHLD3*. RPE1 cells were transfected with siCTRL (non-targeting control siRNA) or siRNA targeting the indicated Shieldin subunits. 48 h post-transfection, mRNA was purified and reverse transcribed before being assayed by quantitative real-time PCR. Data were normalized to the amount of *GAPDH* mRNA and expressed relative

to the corresponding value for cells transfected with siCTRL. Data is presented as the mean ± SD (n=3, independent siRNA transfections). (D) Whole cell extracts from RPE1 WT cells transfected with the indicated siRNAs were processed for immunoblotting with the indicated antibodies. Tubulin is used as a loading control (n=1 experiment; siRNA efficiency is also monitored by immunofluorescence). (E) Quantitation of 53BP1 and RIF1 recruitment to IR-induced DSBs (1 h post-irradiation with 10 Gy) following depletion of the indicated Shieldin components. Data is represented as the mean ± SD (n=3, independent siRNA transfections). (F) Representative micrographs of the experiments quantitated in Supplementary Fig. S4E.





SUPPLEMENTARY FIGURE S5 | Data supporting epistasis

between 53BP1 and Shieldin factors. (A) Quantitation of RAD51 focus formation 3 h post-irradiation (10 Gy) in RPE1 BRCA1-KO (left panel), BRCA1-KO/53BP1-KO (middle panel) and BRCA1-KO/SHLD2-KO (right panel) cells after viral transduction with the indicated sgRNAs (editing efficiency can be found in Supplementary Table 2) or empty vector (EV). Data is represented as the mean \pm SD (for BRCA1-KO 53BP1-KO, n=4 biologically independent IF experiments; for BRCA1-KO and BRCA1-KO SHLD2-KO, n=6 biologically independent IF experiments). P-values were calculated using a two tailed unpaired t-test. Left panel: BRCA1-KO EV vs sg53BP1-1 $p=0.0002$; EV vs sgSHLD1-1 $p=0.0043$; EV vs sgSHLD2-2 $p=0.0348$; EV vs sgSHLD3-1 $p=0.0180$; EV vs sgREV7-1 $p=0.0012$. Middle and right panel: all comparisons to the EV condition were non-significant (ns). Values for BRCA1-KO 53BP1-KO EV vs sg53BP1-1 $p=0.2332$; EV vs sgSHLD1-1 $p=0.4451$; EV vs sgSHLD2-2 $p=0.9632$; EV vs sgSHLD3-1 $p=0.1187$; EV vs sgREV7-1 $p=0.0568$. Values for BRCA1-KO SHLD2-KO: EV vs sg53BP1-1 $p=0.0550$; EV vs sgSHLD1-1 $p=0.1864$; EV vs sgSHLD2-2 $p=0.3568$; EV vs sgSHLD3-1 $p=0.4641$; EV vs sgREV7-1 $p=0.2888$. (B) Talazoparib sensitivity of WT or two independent SHLD1-KO SUM149PT-dox-Cas9 clones (A and D) virally transduced with an sgRNA targeting 53BP1 (sg53BP1) or a control non-targeting sgRNA (sgCTRL), following induction of Cas9. Data is presented as the mean \pm SD (n=3 biologically independent experiments).

SUPPLEMENTARY FIGURE S6 | Data supporting the co-localization of Shieldin with RIF1 on chromatin.


(A) Representation of the deletion mutants of SHLD2N used in Supplementary Fig. S6C-D. The orange shading indicates blocks of homology. (B) Schematic of the LacR-RIF1 chromatin recruitment assay. (C) Quantitation of the experiment shown in Supplementary Fig. S6D. Colocalization was considered positive when the average GFP intensity at the mCherry focus was 3-fold over background nuclear intensity. A minimum of 20 cells were imaged per biological replicate (circles); the bar represents the mean \pm SD ($n=3$). (D) Representative images of the data quantitated in Supplementary Fig. S6C. The main focus is shown in inset and the scale bar = 10 μ m. (E-H), Quantitation (E,G) and representative micrographs (F,H) of overexpressed GFP-SHLD2N and mCherry-LacR-RIF1(1-967) co-transfected into uninduced U2OS-FokI cells along with siRNA against Shieldin complex subunits after processing for mCherry and GFP (E,F) or mCherry and REV7 (G,H) immunofluorescence. Colocalization was considered positive when the average GFP or REV7 intensity at the mCherry focus was 3-fold over background nuclear intensity. A minimum of 20 cells were imaged per condition (circles); the bar represents the mean \pm SD ($n=3$ biologically independent experiments). (I) Representative images of the data quantitated in Supplementary Fig. S6J. The main focus is shown in inset and the scale bar = 10 μ m. (J) Quantitation of GFP intensity at the mCherry-LacR-RIF1(1-967) focus, normalized to nuclear background. Each data point represents a cell transfected with the vector coding for the indicated GFP fusion. The line is at the median. The data is an aggregate of three independent experiments with a minimum of 20 cells counted (total cells counted: 62, 60, and 61 for GFP, GFP-SHLD2C, and GFP-SHLD3, respectively). (K) mCherry-LacR-FokI colocalization with full length or N-terminally truncated (Δ 1-50) GFP-SHLD2. Mean normalized focus intensity is shown from a total of 59 (SHLD2 full length) or 56 (SHLD2 Δ 1-50) cells counted ($n=2$ biologically independent experiments).






SUPPLEMENTARY FIGURE S7 | Mapping the architecture of the Shieldin complex. (A) Streptavidin pull-down analysis determining which region of SHLD2 associates with the other Shieldin subunits. Whole cell extracts (WCEs) of 293T cells transfected with an expression vector for FLAG-SHLD1, V5-SHLD3, GFP-REV7 and Strep/HA-tagged SHLD2, SHLD2N (residues 2-420), SHLD2C (residues 421-904), or empty Strep/HA vector (EV) were incubated with streptavidin resin and bound proteins were eluted with biotin. WCEs and elutions were analysed by SDS-PAGE and immunoblotting with the indicated antibodies. Tubulin was used as a loading control. Results are representative set of immunoblots from 2 independent experiments. *denotes a non-specific band. (B) Mapping the SHLD3 and REV7 binding sites on the SHLD2 N-terminus through streptavidin pull-downs with different SHLD2 constructs (detailed in Supplementary Fig. S6A) and immunoblotting. Results are a representative of a set of immunoblots from 3 independent experiments. (C) Affinity purification of Shieldin complex components using N-terminally truncated SHLD2(Δ1-50) analyzed by immunoblotting (representative of three independent experiments). (D) Streptavidin pull-down analysis of SHLD2 association with REV7 and SHLD3. 293T cells were transfected with siRNAs and expression vectors for epitope-tagged Shieldin components as indicated (EV, empty Strep/HA vector). WCEs were incubated with streptavidin resin and bound proteins were eluted with biotin. WCEs and elutions were analysed by SDS-PAGE and immunoblotted with the indicated antibodies. Short and long exposures are shown for GFP and V5 immunoblots (n=1). *Figure legend continues on next page.*


◀ (E) Dependency of V5-SHLD3 co-immunoprecipitation with GFP-REV7. 293T cells were transfected with siRNAs and expression vectors for epitope-tagged REV7 and SHLD3 as indicated (EV, empty V5 vector). WCEs were incubated with anti-V5 antibody and protein G resin. Bound proteins were boiled in SDS sample buffer and analysed by immunoblotting with GFP and V5 antibodies (n=1). (F) Association between SHLD3 and RIF1. WCEs of 293T cells transfected with an expression vector for unfused GFP (-) or GFP-SHLD3 (SHLD3) were incubated with GFP-Trap resin. Bound proteins were boiled in SDS sample buffer and analysed by SDS-PAGE and immunoblotting against 53BP1 and RIF1. Results are representative of 2 SHLD3 IPs, utilizing SHLD3 fused to GFP (shown here) and V5 (shown in Fig. 3G) affinity tags.



SUPPLEMENTARY FIGURE S8 | Controls supporting the role of Shieldin in promoting physiological NHEJ. (A) Representative dot plots of the flow cytometry data obtained (of n=3 biologically independent experiments) to assess class switching in Fig. 3H. CSR was determined as the percentage of IgA⁺ cells following stimulation after subtracting the baseline percentage of IgA⁺ cells in the indicated clones (values in brackets). (B-C) Epistasis analysis of Shieldin and 53BP1 in CSR. Shown is the percentage of class switching in CH12F3-2 wild type, single knockout, or double knockout cells (as indicated) following stimulation. Each data point represents a biological replicate; the line represents the mean ± SD (n=3). Genomic editing efficiencies of the sgRNAs can be found in Supplementary Table 2. (D) Whole cell extracts of the indicated CH12F3-3 clones were probed for AID and β-actin (loading control) by immunoblotting and were quantitated by densitometry. Each data point represents a biological replicate; the line represents the mean ± SD (n=9 for WT, n=3 for other samples). (E) Random plasmid integration of linearized pcGFP-c1 conferring G418 resistance. Resistant colonies were quantified after 14 d. Bar represents the mean ± SD with WT cells set at 100% (left panel: n=5, right panel: n=4 except SHLD2-KO (2.7) n=3 biologically independent experiments). (F) Representative images of the plasmid integration assays quantitated in Supplementary Fig. S3E. (G) Unirradiated CH12F3-2 clones (25 Gy) were immunoblotted for RPA2 phosphorylation (a representative set from n=3 biological replicates; data relates to Fig. 3I).



SUPPLEMENTARY FIGURE S9 | Data supporting the role of DSB-targeted SHLD2 in the suppression of HR and the mapping of the SHLD2C-SHLD1 complex binding to ssDNA. (A) Representative micrographs of RPE1 BRCA1-KO/53BP1-KO cells transduced with the indicated GFP-fusion proteins, pre-extracted, fixed and stained for RAD51 and GFP 3 h post-IR (10 Gy). Protein expression was induced for 24 h before IR using 1 µg/mL doxycycline. Data relates to Fig. 4B. Note that due to the pre-extraction required for visualization of RAD51 foci, the visualization of non-FHA tagged SHLD2 is lost. (B) SDS-PAGE analysis of purified SHLD2C-SHLD1 complexes. Strep/HA-SHLD2(421-904)-Flag-SHLD1 complexes were purified from transiently transfected 293T cells. Concentrations of purified proteins were estimated by Coomassie staining and comparison to a standard curve of known BSA concentrations visualized by fluorescence at 700 nm. SHLD2C-m1 and SHLD2CS denote SHLD2C constructs carrying the OB fold m1 mutation and the internal deletion (Δ655-723) corresponding to the naturally occurring splice variant of SHLD2, respectively. Open and filled arrowheads mark the bands corresponding to SHLD2C and SHLD1, respectively. EV refers to empty Strep/HA vector. Shown is a representative stained gel from 2 independent experiments. (C) Representative image of the [³²P]-labeled ssDNA EMSA with SHLD2C-SHLD1 for K_d determination shown in Fig. 4E. (D) Model of the SHLD2-OB fold domains and the engineered mutations (red spheres, point mutations; red ribbons, splice variant deletion). Model relates to Fig. 4B-D.



SUPPLEMENTARY FIGURE S10 | SHLD2 OB-folds are required for suppression of RAD51 IR-induced focus formation.

(A) Quantitation of RAD51 foci 3 h following 10 Gy irradiation in RPE1 *BRCA1-KO/SHLD2-KO* cells complemented with the indicated GFP-tagged SHLD2 constructs via viral transduction. Protein expression was induced with 1 μ g/mL doxycycline for 24 h prior to IR. Each data point is a biological replicate; the bar represents the mean \pm SD ($n=6$ for *BRCA1-KO* untransduced cells, *BRCA1-KO / SHLD2-KO* untransduced and GFP-SHLD2 cells, $n=3$ for remaining cell lines, biologically independent experiments). (B) Representative micrographs of the data shown in Supplementary Fig. S10A. Note that due to the pre-extraction required for visualization of RAD51 foci, the visualization of non-FHA tagged SHLD2 foci is lost. (C) Representative micrographs of RPE1 *BRCA1-KO/SHLD2-KO* cells virally transduced with vectors expressing GFP-tagged SHLD2 WT or its OB-fold m1 mutant (m1), or short splice variant (S), 1 h post 5 Gy IR. Scale bar = 10 μ m. (D) Quantitation of the data shown in Supplementary Fig. S10C. Each data point represents an independent biological replicate counting ≥ 100 cells. Data is represented as mean \pm SD ($n=3$). (E) Whole cell extracts (WCE) of 293T cells co-transfected with Strep/HA-SHLD2 WT, -SHLD2-m1, or -SHLD2-S mutants, and other Shieldin subunits (Flag-SHLD1, V5-SHLD3, and GFP-REV7) were incubated with streptavidin resin and bound proteins were eluted with biotin. WCEs and eluted proteins were visualized by SDS-PAGE and immunoblotting with the indicated antibodies. Results shown are a representative set from 2 independent experiments.

SUPPLEMENTARY TABLE 1 | can be accessed via the online version of this article.

SUPPLEMENTARY TABLE 2 |

cell lines	additional genotype cells (clone)	KO (clone)	sgRNA used for editing	mutation*
RPE1 hTERT +flag-Cas9		TP53 (1.1)	CAGAATGCAAGAAGCCAGCA	322delT
RPE1 hTERT +flag-Cas9 TP53 ⁺ (1.1)		BRCA1 (3.6)	AAGGGTAGCTGTGAAAGGC	4277delTC
		53BP1	TCCAATCCTGAACAAACAGC	218delCA
	BRCA1-KO (3.6)	53BP1 (3.3)	TCCAATCCTGAACAAACAGC	218delCA
		SHLD1 (3.12)	TCTGACTGGCCTTTCACAGC	complex (no WT sequence detected)
		SHLD1 (6)	TCTGACTGGCCTTTCACAGC	246insG; 246insCA
	BRCA1-KO (3.6)	SHLD1 (5.18)	TCTGACTGGCCTTTCACAGC	246insG
		SHLD2 (2.3)	GCCTCGGAGGAAGATCTCTG	1708insT; 1707delG
		SHLD2 (2.5)	GCCTCGGAGGAAGATCTCTG	1706insA
		SHLD2 (2.7)	GCCTCGGAGGAAGATCTCTG	1706insA
	BRCA1-KO (3.6)	SHLD2 (2.6)	GCCTCGGAGGAAGATCTCTG	1706insT
	BRCA1-KO (3.6)	SHLD2 (2.9)	GCCTCGGAGGAAGATCTCTG	1704delAG
	BRCA1-KO (3.6)	REV7	GAGGTCTTGTCTGTGAGCG	KO confirmed by WB (data not shown)
SUM149PT		SHLD1 (5-1-C1)	ATAAGAGATTACGTCCTGC	85del5 + 92insT
		SHLD1 (5-1-C2)	ATAAGAGATTACGTCCTGC	92insCAGCT
		SHLD1 (5-1-C3)	ATAAGAGATTACGTCCTGC	92insCAGCT
		SHLD1 (5-1-C4)	ATAAGAGATTACGTCCTGC	92insCAGCT
		SHLD1 (5-1-C5)	ATAAGAGATTACGTCCTGC	92insCAGCT
		SHLD1 (5-2-C1)	TGACTGGCCTTTCACAGCA	247insT
		SHLD1 (5-3-C2)	GATGGCCTTCGGAATCCC	293delC; 286del7
		SHLD1 (5-3-C3)	GATGGCCTTCGGAATCCC	286del7
		SHLD1 (5-3-C5)	GATGGCCTTCGGAATCCC	286del11; 286del7; 288del5
		SHLD1 (5-5-C1)	GGCCATTGAAAACCTGCGG	371del62
		SHLD1 (5-5-C4)	GGCCATTGAAAACCTGCGG	371del62
CH12F3-2		53bp1 (A)	TTCTAGCCCGCTATCTGATG	KO confirmed by WB (data not shown)
		53bp1 (1)	CAGTGGTGACCACCTAACTC	KO confirmed by WB (data not shown)
		Shld1 (5)	ACACACCCGGGTAGATCCA	55insA
		Shld1 (8)	ACACACCCGGGTAGATCCA	57delT
		Shld1 (21)	ACACACCCGGGTAGATCCA	57delT + CtoG58; 46del10
		Shld2 (1)	AACCTGAGTGATGACTAG	341insC; 338del8
		Shld2 (2)	ACGTTTTGACGACTTCTGTG	249insT; 250del5
		Shld3 (1)	AGTGAAGGAGCAGACCAATG	350del4; 349del7
		Shld3 (2)	GGAAGTTGGACTCATCGTA	149delA; 147delC
	Shld2-KO (2)	Shld1 (6)	ACACACCCGGGTAGATCCA	48del11; 45del16
	Shld2-KO (2)	Shld1 (9)	ACACACCCGGGTAGATCCA	51del7; 48del11
	Shld2-KO (2)	53BP1 (27)	CAGTGGTGACCACCTAACTC	KO confirmed by WB (data not shown)
	Shld2-KO (2)	53BP1 (28)	CAGTGGTGACCACCTAACTC	KO confirmed by WB (data not shown)

alleles are separated by ','

	cell lines	additional genotype cells*	pooled sgRNA transduction/transfection	editing efficiency
PARPi two-colour competitive growth assay				
related to Fig. 1c and ED Fig. 1b	RPE1 hTERT +flag-Cas9 TP53 ^{-/-}	BRCA1-KO (3,6)	sgRNA1 53BP1	80.5%
		BRCA1-KO (3,6)	sgRNA1 RNF8	92.7%
		BRCA1-KO (3,6)	sgRNA1 C20orf196	74.1%
		BRCA1-KO (3,6)	sgRNA2 C20orf196	66.5%
		BRCA1-KO (3,6)	sgRNA1 SCAF1	23.2%
		BRCA1-KO (3,6)	sgRNA2 SCAF1	15.4%
		BRCA1-KO (3,6)	sgRNA1 ATMIN	ND
BRCA1-KO (3,6)	sgRNA2 ATMIN	ND		
Etoposide two-colour competitive growth assay				
related to ED Fig. 1f	RPE1 hTERT +flag-Cas9 TP53 ^{-/-}		sgRNA1 SHLD2	91.7%
			sgRNA2 SHLD2	90.7%
			sgRNA1 SHLD3	58.2%
			sgRNA2 SHLD3	63.5%
Traffic light reporter assay				
related to ED Fig. 2b	RPE1 hTERT +flag-Cas9 TP53 ^{-/-}	BRCA1-KO (3,6)	sgRNA4 53BP1	77.4
		BRCA1-KO (3,6)	sgRNA1 SHLD3	16.5%
Epistasis experiments				
related to ED Fig. 5a	RPE1 hTERT +flag-Cas9 TP53 ^{-/-}	BRCA1-KO (3,6)	sgRNA1 53BP1	52.9%
		BRCA1-KO (3,6)	sgRNA1 SHLD1	51.20%
		BRCA1-KO (3,6)	sgRNA2 SHLD2	88.90%
		BRCA1-KO (3,6)	sgRNA1 SHLD3	77.40%
		BRCA1-KO (3,6)	sgRNA1 REV7	ND (reduced expression of REV7 confirmed by WB (data not shown))
		BRCA1-KO 53BP1-KO (3,3)	sgRNA1 53BP1	100% (mutation already present in KO clone)
		BRCA1-KO 53BP1-KO (3,3)	sgRNA1 SHLD1	59.80%
		BRCA1-KO 53BP1-KO (3,3)	sgRNA2 SHLD2	92.30%
		BRCA1-KO 53BP1-KO (3,3)	sgRNA1 SHLD3	56%
		BRCA1-KO 53BP1-KO (3,3)	sgRNA1 REV7	ND (reduced expression of REV7 confirmed by WB (data not shown))
		BRCA1-KO SHLD2-KO (2,9)	sgRNA1 53BP1	74.40%
		BRCA1-KO SHLD2-KO (2,9)	sgRNA1 SHLD1	55%
		BRCA1-KO SHLD2-KO (2,9)	sgRNA2 SHLD2	100% (mutation already present in KO clone)
		BRCA1-KO SHLD2-KO (2,9)	sgRNA1 SHLD3	83.50%
		BRCA1-KO SHLD2-KO (2,9)	sgRNA1 REV7	ND (reduced expression of REV7 confirmed by WB (data not shown))
mouse BRCA1 tumour model				
related to ED Fig. 3	KB1P-G3		sgRNA Shld1	80.8%
			sgRNA Shld2	94.5%
		Rosa26 ^{CreERT2/loxP} ; Brca1 ^{fl/fl} ; p53-null mES cells	sgRNA1 Shld1	83.9%
			sgRNA Shld2	89.8%
		Rosa26 ^{CreERT2/loxP} ; Brca1 ^{fl/fl} ; p53-null mES cells	sgRNA1 Shld1	92.4%
			sgRNA Shld2	96%
		KB1P4s.1	sgRNA Shld1	97.2%
	sgRNA Shld2	95.9%		

SUPPLEMENTARY TABLE 3 |

BAIT	PREY UNIPROT	PREY	AvgSpec	BFDR
C2oorf196	Q86V20-2	FAM35A	10,2	0
C2oorf196	P13984	GTF2F2	4,8	0
CTC-534A2.2	P40937-2	RFC5	4,33	0
CTC-534A2.2	Q6ZNX1	CTC-534A2.2	45,67	0
CTC-534A2.2	Q9UI95	MAD2L2	30,33	0
CTC-534A2.2	P35249	RFC4	5,33	0
CTC-534A2.2	Q86V20-2	FAM35A	13	0
FAM35A	B5ME19	EIF3CL	10,67	0
FAM35A	Q6ZNX1	CTC-534A2.2	2,83	0,01
FAM35A	Q9UI95	MAD2L2	5,67	0
FAM35A	Q14320	FAM50A	5,33	0,01
FAM35A	Q8IYI0	C2oorf196	3	0,02
MAD2L2	NP_000407.1	IFNGR1	4,17	0
MAD2L2	P11717	IGF2R	3	0,01
MAD2L2	P08195-2	SLC3A2	14,17	0
MAD2L2	NP_001122103.1	DCAKD	8,67	0
MAD2L2	NP_001128582.1	DNAJA3	8,83	0
MAD2L2	NP_001153101.1	SLC27A2	5	0
MAD2L2	NP_001157616.1	CHAMP1	97,83	0
MAD2L2	O75306-2	NDUFS2	5,83	0
MAD2L2	NP_001161086.1	LEMD3	6,33	0
MAD2L2	O43819	SCO2	6,67	0
MAD2L2	P40616-2	ARL1	7,33	0,02
MAD2L2	NP_001181866.1	POGZ	5,33	0
MAD2L2	NP_001240795.1	YME1L1	10,17	0
MAD2L2	P53007	SLC25A1	3	0,01
MAD2L2	O00217	NDUFS8	4,33	0
MAD2L2	NP_002903.3	REV3L	3,5	0,01
MAD2L2	O14735-3	CDIPT	3,83	0
MAD2L2	O00264	PGRMC1	19,33	0
MAD2L2	Q13015	MLLT1	11,67	0
MAD2L2	NP_036610.2	WBP2	5,17	0
MAD2L2	Q9P032	NDUFAF4	8,5	0
MAD2L2	NP_056036.1	DNMBP	33	0
MAD2L2	NP_056146.1	NCSTN	2,67	0,01
MAD2L2	NP_057191.2	ZFR	3,17	0
MAD2L2	NP_057540.1	TMEM9	2,83	0,01
MAD2L2	NP_061158.1	BIN3	11,83	0
MAD2L2	Q86V20-2	FAM35A	14,67	0
MAD2L2	NP_065770.1	PRR12	7,33	0
MAD2L2	Q8N163-2	CCAR2	18,17	0
MAD2L2	Q8WVC4	MAIP1	5,17	0
MAD2L2	NP_115604.1	FAR1	4,5	0
MAD2L2	NP_149014.3	SYDE1	4,67	0
MAD2L2	P51648-2	ALDH3A2	11	0
MAD2L2	NP_001035997.2	COASY	17,33	0
MAD2L2	NP_001129629.1	OTUD5	15	0
MAD2L2	P78347-2	GTF2I	207,83	0
MAD2L2	P10321	HLA-C	4,67	0
MAD2L2	O95573	ACSL3	7,67	0,02
MAD2L2	Q9Y4W6	AFG3L2	15,33	0
MAD2L2	NP_036560.1	NPTN	7	0
MAD2L2	NP_001230648.1	RAB6A	3,33	0,01
MAD2L2	NP_079348.1	PTGES2	4,5	0
MAD2L2	Q9NXS2-3	QPCTL	3	0,01
MAD2L2	Q6ZNX1	CTC-534A2.2	3,5	0,01
MAD2L2	NP_001159575.1	SPINT2	4	0
MAD2L2	NP_859052.3	QSOX2	4	0
MAD2L2	NP_000296.2	PON2	2,33	0,02
MAD2L2	Q8IYI0	C2oorf196	2,67	0,02
MAD2L2	AoFGR8-2	ESYT2	2,5	0,02
MAD2L2	NP_004228.1	TRIP13	3,5	0
CTC-534A2.2	Q8IYI0	C2oorf196	2	0,17
C2oorf196	Q9UI95	MAD2L2	0,8	0,41
C2oorf196	Q6ZNX1	CTC-534A2.2	0,2	0,93

SUPPLEMENTARY TABLE 4 | CAN BE ACCESSED VIA THE ONLINE VERSION OF THIS ARTICLE.

SUPPLEMENTARY TABLE 5 |

targeting gene	sgRNA sequence	Usage	
		RPE1 cells	SUM149PT cells
LacZ control	CCCGAATCTCTATCGTCCGG	√	
TP53	CAGAATGCAAGAAGCCAGA	√	
BRCA1	AAGGGTAGCTGTTAGAAGGC	√	
53BP1 gRNA1	TCCAATCCTGAACAAACAGC	√	
53BP1 gRNA4	CACCGACCTTCTCAATAAAGTTGAT	√	
53BP1 gRNA5_1	TCTAGTGTGTTAGATCAGG		√
53BP1 gRNA5_3	GACTGCTAGGAACGATAAA		√
53BP1 gRNA_A10	GCACAAGAACTTATGGAAAAG		√ (used for epistasis experiment (Supplementary Figure S5B))
C20orf196 gRNA1	TCTGACTGGCCTTTCACAGC	√	
C20orf196 gRNA2	ATCTATCCAGGATTTCCGA	√	
C20orf196 gRNA5_1	ATAAGAGATTACGTCCTGC		√
C20orf196 gRNA5_2	TGACTGGCCTTTCACAGCA		√
C20orf196 gRNA5_3	GATGGCCTTCGGAAATCCC		√
C20orf196 gRNA5_4	ATTTTCATAGAATCTATCCA		√
C20orf196 gRNA5_5	GGCCATTTGAAAACCTGCGG		√
FAM35A gRNA1	CAAGGTCTGAAGCAGCAGTT	√	
FAM35A gRNA2	GCCTCGGAGGAAGATCTCTG	√	
CTC534A2.2 gRNA1	TGTGAGAGTGATCCACACA	√	
CTC534A2.2 gRNA2	AACTTGTCACACACTGA	√	
RNF8 gRNA1	AAGGGTCTGTGGAGCGGA	√	
RNF8 gRNA2	CCCAGAGTCTAAATGGTGTT	√	
SCAF1 gRNA1	CCACGGACAGCTTCTCGCA	√	
SCAF1 gRNA2	CAACCTGGCGAGCCGAGCGA	√	
REV7 gRNA1	GAGGCTTGTGCTGTGAGCG	√	
REV7 gRNA2	GTGCGGAGGTCTACCCCGT	√	
PTIP gRNA1	GGAGGTCAAGTATTACCCGG	√	
PTIP gRNA2	GTGTGAGGCTAGTGCATTGT	√	
ATMIN gRNA1	GATGTTGGTCCGCACGGCCC	√	
ATMIN gRNA2	GGATGTTGGTCCGCACGGCCC	√	
PARP1 gRNA5_2	GACCCGAGCATTCTCCGA		√
PARP1 gRNA5_4	GCTAGGCATGATTGACCCG		√
Control [Targets a mouse olfactory receptor]	CAACAGTCGATCCCAAGA		√ (used for epistasis experiment (Supplementary Figure S))
Nontargeting	AAAACACGATGACGTCTCT		√ (for crRNA experiments)

targeting gene	sgRNA sequence	Usage		
		mES	KB1P-G3, KB1P45	CH12F3-2
Trp53bp1_e6_834	CAGTTGGTGACCACTAACTC			√
Trp53bp1_e6_857	TTCTAGCCCCCTATCTGATG			√
Shld1 gRNA1	GATCAGTAGTCGAAGAAGAA	√		
Shld1 gRNA2	ACACACCCCGGTAGATCCA		√	√
Shld1 gRNA2_2	GGCCCCGGTCCACCCGCC			√
Shld2 gRNA1	ATCAGTCAGATCCCTGCGTT	√	√	
Shld2_e4_772	ACGTTTTGACGACTTCTGTG			√
Shld2_e4_864	AACCTGAGTGATGACTAG			√
Shld3_e2_686	GACTCATCGTATGGAAACCA			√
Shld3_e2_695	GGAAGTTGGACTCATCGTA			√
Shld3_e2_905	AGTGAAGGAGCAGACCAATG			√
non targeting gRNA	TGATTGGGGTCTGTCGCA	√		

SUPPLEMENTARY TABLE 6 |

targeting gene	genomic locus	forward primer	reverse primer	for sequencing
BRCA1	gRNA 1	TCTCAAAGTATTTTCATTTCTTGGTGCC	TGAGCAAGGATCATAAAATGTTGG	
53BP1	gRNA 1	CCAGCACCAACAAGAGC	GGATGCCTGGTACTGTTTGG	
53BP1	gRNA 4	CCTTTTATCCTTGGATGAGGCA	CTGAAAGCCAGGTTCTAGAGGATGA	
C20orf196	gRNA1+2	GGCTAAGAATCCTTGGTCCACA	GGCTCTCTGGCCTCTTAGTT	
C20orf196	gRNA 5_1	ACAAAATAACTCTGGACCGC	CCTGGGTTTGGCTTTTCATCA	
C20orf196	gRNA 5_2 to 5	AGGATCCTGCTATGTGGTGC	ATCACACACCCGTATTGCTG	
FAM35A	gRNA 1	CCAGAATCTATTGGTCTCCAGA	GAGTTTATGTGAATCGGGCT	
FAM35A	gRNA 2	GGAACCAATTGGCTGTACA	CCATAATACAAGCGCATAATGT	
CTC534A2.2	gRNA 1+2	CATTGTCTCAATTTAAGTTGCCTC	GTGTTCTATTGTCCATCTTGCTC	TTCTTTTCTCCCTGCCTGTTG
RNF8	gRNA 1	TGAGAAGAGGTTCCAGTCTGG	ACAGACACTTCGCTCCTCTTC	
RNF8	gRNA 2	AGCAGCAGGAGAGAGATTCC	CCCTGAAGACCACTCTTGC	
RNF168	gRNA 1+2	GGACAAAATCTGCCCTTGAC	GAGCAGCCAGGCTCTCC	
SCAF1	gRNA 1	GGAGAGTCTGGGGCCTGATC	GATCACCGTACCATCACTACC	
SCAF1	gRNA 2	CACTCCTGCCACTGTCTCATC	CTTTCTGTGGCTGAGGATCTG	GGTATGGGCTGTCTCTCATT
REV7	gRNA 1+2	TGTCAACCAGGCTGGAATGC	GGGAACCTGGGGAAGGACCT	
PTIP	gRNA 1	TTGTAATCCCAGCTACTCAGG	CATCTGTCTTGAGACAGACC	
PTIP	gRNA 2	TAGGGGCCGAGGTACAGAGC	GAGCGGACCCCGATTGCG	
ATMIN	gRNA 1+2	ACGACAGGAGCCCGCC	TTCGAGAGCCGCTCCGGCC	

targeting gene	genomic locus	forward primer	reverse primer
C20orf196	gRNA1 and 2	ATTTGTCATTATGTCTGGCTCC	TTGGCCAATTCAAAAGTGTGC
C20orf196	gRNA2_2	ATTTGTCATTATGTCTGGCTCC	TTGGCCAATTCAAAAGTGTGC
Trp53bp1	e6	GCTACCACACCCAGTCTGAT	CAGCACTCACAACAATGGCT
Fam35a	gRNA1	TCTGCTCAGTGGATGAGGA	CCTGTTGTTCTGCCTCCAT
Fam35a	e4	ATATGTGGTAGTGTGGGCCG	ACCGTGTGCAGAGAAGCTC
Shld3	e2	AGCTCTGAAGAATTCAGCTAAGAAA	TCCATATTCATTCATTGAGAATTC
HPRT	qPCR primers	CCCAGCGTCGTGATTAGC	GGAATAAACACITTTTCCAAAT
μ germline transcript	qPCR primers	CTCTGGCCCTGCTATTGTTG	CTGACTCTGGTGGCAGAAAG
α germline transcript	qPCR primers	CCTGGCTGTCCCCTATGAA	GAGCTGGTGGAGTGTGAGTG

SUPPLEMENTARY TABLE 7 |

Primary antibodies	Company	WB dilution	IF dilution
Rb anti RAD51	Santa Cruz, sc-8349		1:150
Rb anti RAD51	Bio Academia, #70-001		1:2,000
Rb anti REV7	Abcam, ab180579	1:1,000	1:500
Rb anti 53BP1	Santa Cruz, sc-22760		1:5,000
M anti 53BP1	Becton Dickinson, #612523	1:1,000-3,000	
G anti RIF1	Santa Cruz, sc-55979	1:1,000	1:200
R anti RIF1	Bethyl A300-569A	1:7,500	
M anti γ H2AX	Millipore, #05-636		1:5,000
Rb anti BRCA1	homemade	1:1,000	
Rb anti pRPA32 (S4/S8)	Bethyl, A300-245A	1:1,000	
Rb anti KAP1	Bethyl, A300-274A	1:2,000	
M anti Tubulin	Calbiochem, CP06	1:2,000	
M anti Tubulin	Sigma, T6199	1:5,000	
Rb anti Flag	Cell Signalling Technologies, #23685	1:2,000	
M anti Flag-HRP	Sigma, A8592	1:1,000	
G anti GFP	Homemade by Pelletier lab, Lunenfeld-Tanenbaum Research Institute	1:5,000	
Rb anti GFP	Abcam, ab290	1:1,000-5,000	1:2,000
M anti GFP	Roche, #11814460001		1:2,000
M anti V5	Invitrogen, #46-0705	1:1,000	
M anti HA	Biolegend, #901502	1:1,000	
G anti mouse IgA-PE	Southern Biotech #1040-09		FACS: 1:100-150
M anti-AID	Cell Signaling Technologies, #4975	1:1,000	
Anti- β -actin	Sigma	1:2,000	

Secondary antibodies	Company	WB dilution	IF dilution
HRP-tagged Rabbit anti Mouse	DakoCytomation, P0260	1:5,000	
HRP-tagged Goat anti Rabbit	Jackson Laboratories, #111-035-144	1:5,000	
HRP-tagged bovine-anti-goat	Jackson Laboratories, #805-035-180	1:5,000	
IRDye-conjugated Goat anti Mouse	Li-cor, #926-32210	1;10,000	
IRDye-conjugated Goat anti Rabbit	Li-cor, #926-68071	1;10,000	
AlexaFluor-488 Goat anti Mouse	Invitrogen, A-11029		1:1,000
AlexaFluor-488 Goat anti Rabbit	Invitrogen, A-11034		1:1,000
AlexaFluor-488 Donkey anti Goat	Invitrogen, A-11055		1:1,000
AlexaFluor-555 Goat anti Mouse	Invitrogen, A-21424		1:1,000
AlexaFluor-555 Goat anti Rabbit	Invitrogen, A-21429		1:1,000
AlexaFluor-647 Goat anti Mouse	Invitrogen, A-21236		1:1,000
AlexaFluor-647 Goat anti Rabbit	Invitrogen, A-21245		1:1,000
Alexa fluor 568 F(ab'), Fragment goat anti-rabbit	Invitrogen, A-21069		1:1,000